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Den mätta dagen, den är aldrig störst. 
Den bästa dagen är en dag av törst. 
 
Nog finns det mål och mening i vår färd –  
men det är vägen som är mödan värd. 
 
Karin Boye (1900-1940). Från I rörelse/On the Move (Ur Härdarna, 1927). 
 
The day of plenty, never is the greatest. 
The best day is a day of craving thirst. 
 
Yes, there is a meaning in our journey – 
but ‘tis the pathway, which is worth our while. 
 
The excerpt from the poem by Karin Boye is published with kind permission from Mats Boye and from Hans 
Corell, who made the translation. 
 
 
 
 
 
To my family 
 
 
  
ABSTRACT 
Maternal smoking is one of the most important preventable risk factors in pregnancy. 
Whether it is nicotine or combustion products, or possibly both, that cause the adverse effects 
is not clear. The common substance in snuff and cigarette smoke is nicotine.The main 
objective was to study whether it is safe to use snuff in pregnancy, and if cessation of tobacco 
use influences the risk of adverse effects on the health of the newborn.  
Methods: Studies I-III were all based on data from the Swedish Medical Birth Register. 
Information on tobacco use three months before pregnancy and in early pregnancy was 
obtained from the register and categorized as nonuser, smoker 1-9 cigarettes/day, smoker≥10 
cigarettes/day or snuff user. Most epidemiological studies on tobacco use are based on self-
reported information. Snuff use in pregnancy has not been validated previously. In study IV, 
self-reported snuff use in a cohort of pregnant women was validated by the use of a 
biomarker of nicotine exposure, cotinine. 
Results: In study I, the association between smoking or snuff use in pregnancy and risk of 
neonatal apnea was investigated. Maternal snuff use was associated with an almost twofold 
risk of neonatal apnea. In contrast, the increased risk of apnea in smokers was not significant 
after adjustment for gestational age, indicating different mechanisms for nicotine and tobacco 
smoke.  
Study II investigated the association between tobacco use and risk of oral cleft 
malformations. Both maternal smoking and snuff use were associated with increased risk of 
oral cleft malformations. However, infants of women who had stopped smoking or using 
snuff before the antenatal booking were not at an increased risk of oral cleft malformations 
compared to that of nonusers. 
In study III, the association between maternal smoking, snuff use and preterm birth was 
studied. Maternal smoking was associated with extremely (<28 weeks), very (28-<32 weeks) 
and moderately (32-<37 weeks) preterm birth. Snuff use in pregnancy was associated with 
extremely preterm birth and moderately preterm birth, whereas the association with very 
preterm birth was of borderline significance. Importantly, with cessation of tobacco use in 
early pregnancy, there was no increased risk. 
In Study IV, self-reported snuff use was validated by measuring cotinine in maternal urine 
and meconium of the newborn. Self-reported use of snuff was found valid in late pregnancy. 
However, there was a large proportion of misclassification of snuff use in the Medical Birth 
Register in late pregnancy. 
Conclusion: Snuff use and smoking in pregnancy are associated with increased risk of 
adverse effects such as neonatal apnea, oral cleft malformation and extremely preterm birth. 
Importantly, infants of women who stopped using tobacco were not at an increased risk. This 
thesis indicates that no forms of nicotine or tobacco are to be regarded as safe to use in 
pregnancy. 
SVENSK SAMMANFATTNING 
Globalt är rökning en av de främsta förebyggbara riskfaktorerna under graviditet. Rökning 
under graviditet är associerad med en ökad risk för placentablödning, prematur födsel, 
intrauterin dödföddhet, tillväxthämning hos fostret och ökad morbiditet och mortalitet i 
nyföddhetsperioden. Rökning under graviditet ökar också risken för plötslig spädbarnsdöd. 
Huruvida det är nikotin eller förbränningsprodukter i cigarettrök som orsakar de skadliga 
effekter som ses hos barn till rökare är inte helt klarlagt. Det är dock en viktig fråga, eftersom 
det i Sverige finns en utbredd användning av snus. Till skillnad från cigaretter innehåller snus 
inga förbränningsprodukter men däremot nikotin. 
Syftet med denna avhandling var att undersöka effekterna på fostret av prenatal 
nikotinexponering i form av snus för att bedöma huruvida snus är säkert att använda under 
gravididitet, samt om snusstopp i tidig graviditet påverkar eventuella risker. 
Studie I visade att rökning och snusanvändning ökade risken för andningsuppehåll (apné) i 
nyföddhetsperioden. Den ökade risken för neonatal apné hos barn till rökare förklarades av 
den ökade risken för prematur födsel. Hos barn till snusare kvarstod den fördubblade risken 
också efter justering för prematuritet. 
Studie II visade att både rökning och snusanvändning ökade risken för läpp-käk-gomspalt 
(LKG) missbildning. Kvinnor som slutat röka eller snusa i tidig graviditet, före första besöket 
hos mödravården, hade ingen ökad risk för att föda ett barn med LKG-missbildning. 
Studie III visade att både rökning och snusanvändning under graviditet ökade risken för 
prematur födsel. Rökning ökade risken för extremt, mycket och måttligt för tidig födsel, 
medan snusanvändning i graviditet var associerad med ökad risk för extremt prematur födsel 
och måttligt prematur födsel. Hos varken rökare och snusare sågs någon ökad risk för 
prematur födsel vid rök- eller snusstopp i mycket tidig graviditet. 
Studie IV visade att självrapporterad snusanvändning under graviditet är valid i Sverige. 
Dock påvisades en omfattande missklassificering av kvinnor i sen graviditet i Medicinska 
födelseregistret. Kvinnor med kotininnivåer som indikerade tobaksanvändning samt som 
rapporterat snusanvändning under graviditet i studiens frågeformulär var registrerade som 
icke-tobaksanvändare i MFR. 
Sammanfattningsvis var både rökning och snusanvändning under graviditet associerade med 
en ökad risk för andningsuppehåll i nyföddhetsperioden, LKG-missbildning samt extremt för 
tidig födsel. Ett viktigt folkhälsobudskap är att vid rök- och snusstopp i tidig graviditet ses 
inga förhöjda risker. Samtliga studier i denna avhandling pekar på att snus liksom rökning är 
förenade med allvarliga skadeverkningar för fostret och den nyföddes hälsa. Cigaretter, snus 
och andra nikotinprodukter bör inte användas under graviditet. 
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1 INTRODUCTION 
Smoking is one of the most important avoidable risk factors in pregnancy worldwide. 
Maternal smoking is causally related to preterm birth and fetal growth restriction and 
associated with adverse pregnancy complications, like ectopic pregnancy, placenta abruption, 
stillbirth, preterm birth and intrauterine growth restriction (IUGR).
1
 Smoking in pregnancy is 
also associated with detrimental effects on the health of the newborn, such as an increased 
risk of sudden infant death syndrome (SIDS). Furthermore, maternal smoking is associated 
with long-term effects such as asthma and respiratory disease in childhood and morbidity 
caused by prematurity and intrauterine growth restriction.
2, 3
  
The prevalence of smoking during pregnancy ranges from 5-20% in the Unites States and the 
European countries.
2, 4, 5
 In Sweden, the prevalence of smoking during pregnancy is only 5%.
6
 
In Sweden, smokeless tobacco in the form of moist oral snuff, or snus, is widely used, also 
among women. Snuff use is most common among young women in reproductive age and the 
prevalence of snuff use in pregnancy is 1.3%.
6, 7
 
Cigarette smoke contains nicotine and numerous combustion products. Despite the common 
perception that nicotine is responsible for many of the adverse effects of smoking in 
pregnancy, there is an ongoing discussion of whether it is safe to use nicotine-replacement 
therapy, NRT, in pregnancy.
8-10
 Randomized controlled trials on NRT have been difficult to 
interpret from because of lack of compliance.
11
  
Swedish snuff contains nicotine but no combustion products.
12, 13
 Thus, studying snuff use in 
pregnancy offers an opportunity to differentiate between effects caused by combustion 
products in cigarette smoke and those caused by nicotine in snuff. 
At the end of the 20
th
 century, snuff use among women aged 16-24 almost tripled.
14
 
International researchers and policy makers, including the tobacco companies, proclaimed 
Swedish Snuff, or snus, as a harm reduction product in the struggle against smoke-related 
morbidity and mortality in high income countries.
13, 15-17
 However, there was very little 
knowledge about the effects of using snuff in pregnancy.  
Even though it is probably better for the health of the pregnant woman to switch from 
cigarettes to snuff, it does not necessarily mean that it is also better for the health of the 
newborn. The main aim of this thesis was to investigate if nicotine, in the form of snuff, is 
safe to use in pregnancy. 
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Figure 1. Cigarette advertising 
 
Source: From the collection of Stanford Research Into the Impact of Tobacco Advertising 
(tobacco.stanford.edu).  
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2 BACKGROUND  
“I say, if you can´t send money, send tobacco.” 
US President George Washington´s request to help finance the American Civil War (1776) 
The earliest cultivation of the tobacco plant is believed to have occurred in America in around 
6000 B.C. Christopher Columbus discovered the plant in 1492 and brought it to Europe, and 
from Europe it spread to the European colonies in Africa and Asia. It was originally believed 
to have healing properties and was used in medicine.
5
  
Throughout history, the mode of nicotine use has changed from mainly chewing tobacco or 
inhaling dry tobacco powder as snuff to cigar and cigarette smoking.  
World War I (1914-1918) effectively spread the habit of smoking, and with the rise of the 
manufactured cigarette in the 20
th
 century the use of cigarettes exploded. Tobacco companies 
marketed cigarettes for women, and smoking rates among female teenagers tripled in the 
years 1925-1935. During World War II (1939-1945), cigarette sales increased to all time high 
levels.
2
  
In the 50´s and 60´s, smoking was associated with success and fame. Manufactured cigarettes 
were very common among both men and women in the Unites States (US) and Europe.
2, 18
 At 
the same time the first major reports on hazardous effects of smoking were published. In 
1950, Richard Doll stated that smoking was causally related to lung cancer,
19
 and in1964 the 
Surgeon General's report on "Smoking and Health" showed hazardous effects of smoking on 
health.
2
 
2.1 THE PREVALENCE OF SMOKING 
“…the current lower level of tobacco use among women in the world…does not reflect health 
awareness, but rather social traditions and women’s low economic resources.”  
Dr. Gro Harlem Brundtland, Director General, WHO, 1998 
Globally, approximately 967 million men and women smoke daily.
20
 The top five high 
consumption countries of cigarettes in the world are China, Japan, the US, Russia and 
Indonesia.
5
 China is the largest tobacco consuming nation in the world, and one third of all 
smoking men in the world live in China. According to the World Health Organization 
(WHO) Global Adult Survey data, 2010, the prevalence of smoking among men in China was 
53%.
5, 20, 21
 
In the last 30 years, the estimated prevalence of smoking in the world has decreased, but 
because of population growth the total number of smokers has increased.
20
 There has been a 
shift in smoking prevalence from high-income countries, where smoking is declining, to low-
income countries and developing countries where the smoking prevalence is continuously 
high. In some countries, such as Africa and Eastern Europe, the prevalence is actually 
rising.
20, 21
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In the US, the prevalence of cigarette smoking has declined from 42% in 1965 to 18% in 
2012.
2
 The decline of smoking is seen in both men and women and in all age-groups. In the 
US, there are today more former smokers than smokers and it is estimated that more than 
50% of ever smokers have quit smoking.
2
 
Figure 2. The prevalence of smoking in Europe, 201 
 
Source ’Special Eurobarometer 429’, European Commission, 2015 
The average smoking prevalence in Europe is approximately 26%, with great diversity 
between countries.
4
 Smoking is more common in southern and eastern Europe with the 
highest prevalence in Greece (40%), Bulgaria (36%) and Latvia (36%), in comparison to 
Sweden, where the smoking prevalence is around 10%.
4, 7
 In the United Kingdom (UK), 
Sweden and many other European countries, smoking has decreased considerably among 
both men and women since the 1970’s and 1980’s. 
2.2 DEFINITION AND PREVALENCE OF SMOKELESS TOBACCO 
Smokeless tobacco (ST) is an umbrella term for a wide range of tobacco products that are not 
smoked. When used orally, ST is often used in the form of oral moist snuff, such as Swedish 
snus, and as chewing tobacco. It can also be sucked, applied to the gums as a paste, dissolved 
in the mouth, gargled or inserted in betel quid. ST can also be inhaled as a powder, called dry 
snuff.
22
  
Over 300 million people around the world use smokeless tobacco. The vast majority, 89%, 
live in South Asia, especially India and Bangladesh, where the variety of products is large. In 
these countries, the most commonly used ST products are betel quid with tobacco, khanini 
and products applied to teeth and gum, like gul and mishri. The prevalence of ST use in India 
and  Bangladesh is 25.9 % and 27.2%, respectively.
23
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In Europe and North America, the most common ST products are chewing tobacco and oral 
moist snuff. In the US, 7.1% of males use oral moist snuff. 
23
 In Scandinavia, and in Sweden 
in particular, oral moist snuff, or Swedish snus, is most widely used, with a prevalence of 
20% among males and 3-4% among females.
7
 
The diversity of ST products, combined with differences in characteristics between ST users 
in different regions of the world, makes health implications of ST use difficult to generalize. 
In this thesis, snuff use will be defined as the use of Swedish snus. Other forms of ST will not 
be discussed further. 
Figure 3. Smokeless tobacco products 
 
Source: Smokeless tobacco and public health: A global perspective, National Cancer Institute Centers for 
Disease Control and Prevention U.S. Department of Health and Human Services 
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2.3 SMOKING AND SNUFF USE IN SWEDEN 
 
“EG? Inte utan min prilla!” 
“The EU? Not without my pouch of snuff.” (Bumper sticker attributed to Anders Andersö, “Tecknar-
Anders”, in the campaign for Swedish snuff 1994) 
At the beginning of the19th century, snuff, in the form of oral moist snuff, became 
increasingly common and was used mainly by working class men in Sweden. In 1915, AB 
Svenska Tobaksmonopolet, today known as Swedish Match, was founded, and after World 
War I the use of snuff use peaked in Sweden with a consumption of 1.2 kg/per capita.
18
 After 
World War II, though, cigarette smoking grew popular and was associated with fame and 
high social class. As a consequence, snuff use in Sweden declined substantially. In the 
1960’s, with 50% of all Swedish men being smokers, it was even discussed to stop the 
production of snuff altogether in Sweden. However, with increasing knowledge of the 
hazardous effects of smoking, the number of smokers has declined since the 1970’s, and as a 
consequence the use of snuff, which is regarded as less harmful, has increased. In 1973, 
portions of snuff were launched as a popular alternative to loose snuff.
18, 24
 
Figure 4. Tobacco consumption, cigarettes and snuff from 1916-2015. 
 
Source: Published with permission from Swedish Match 
Smoking has continued to decline in both sexes, but Sweden is one of the few countries in the 
world where more women than men smoke. The prevalence of smoking among women was 
11% and among men 9% in 2016.
7
 In contrast, most snuff users are men. Approximately, 
20% of Swedish men and 3-4% of Swedish women use snuff. It is primarily young women in 
fertile age, aged 16-29 , who use snuff daily (4%) and sporadically (3%).
7
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Important dates for the tobacco policy in Sweden 
Tobacco Act 2016 (SFS 2016:353) 
 EU countries are required to have spacious health warnings with text and images 
on cigarette packs, on more than 65% of the size of the package. 
 The text on tobacco products is not allowed to propose that the product is a 
healthier product in comparison to other tobacco products.  
 No information about proportions of nicotine, tar and carbon monoxide is allowed. 
 Information on taste or smell additives is not allowed on tobacco products, with 
the exception of snus.  
EU membership 1995 
 At the time of Sweden’s entry into the EU 1995, tobacco products for oral use, 
except smoking or chewing tobacco, were been banned. As Swedish snus is 
neither smoked nor chewed it is prohibited for sale in EU. However, Sweden was 
granted a permanent exemption from the sales ban on snus. 
Tobacco Act 1993 (1993:581) 
 Ban of commercial advertising of tobacco products. 
 Ban of smoking in public places, with the exception of outdoor seating at cafés 
and restaurants. 
 
 14 
 
Source: Photo by Henrik Dahl, 2017 
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2.4 CHARACTERISTICS OF TOBACCO USERS 
“It is important to know as much as possible about teenage smoking patterns and attitudes. 
Today´s teenager is tomorrow´s potential regular customer, and the overwhelming majority 
of smokers first begin to smoke while still in their teens. The smoking patterns of teenagers 
are particularly important to Philip Morris.” Philip Morris Companies Inc. 1981 
Tobacco use is correlated with social inequalities. Globally, high-income countries have 
lower prevalence of smoking than developing countries.
20
 Both smoking and use of ST is 
more common in rural than in urban areas. Use of tobacco is correlated with lower education, 
unemployment, poverty, consumption of alcohol and substance use, as well as with 
psychiatric illness.
2, 4, 23, 25
 More than 80% of smokers begin before 18 years of age, and 
smokers who started smoking early are less likely to quit.
1
 
Worldwide, more men than women use tobacco. However, the gender differences in tobacco 
use vary between countries and cultural contexts. In many of the countries with the highest 
prevalence of smoking, like China, Eastern Europe, Russia and Asia, men smoke 10 times 
more than women.
5
 In contrast, in high income industrialized countries, the gap between 
women and men is declining. According to the WHO report on the global tobacco epidemic 
2015, 19% of females in Europe smoked tobacco, in comparison to 2-3% in Africa, Southeast 
Asia and the Eastern Mediterranean and Western Pacific Regions.
21
 Sweden and Norway are 
exceptions with higher smoking prevalence among women than men.
7
  
Also the use of smokeless tobacco shows gender differences. The majority of ST users 
worldwide are men, but in some countries, as for example India (18.4%), Bangladesh 
(26.4%), and South Africa (10.9), the prevalence among women is very high.
23
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2.5 SUBSTITUENTS OF TOBACCO 
Smoked tobacco contains more than 4000 
different chemicals, including nicotine, carbon 
monoxide, CO, tobacco specific nitrosamines 
(TSNA), polycyclic aldehydes (PAH), nitrate 
and aromatic amines. It also contains heavy 
metals like cadmium, arsenic, lead, nickel, 
chrome, mercury and polonium.
3
 The 
concentration of heavy metals in tobacco is 
much dependent on the concentration in the 
soil where tobacco is grown.
23
 The levels of 
TSNA are especially frequent in fire-cured 
tobacco, but also dependent on the level of 
nitrate producing bacteria. PAH and 
formaldehydes are carcinogenic and formed 
when tobacco is burned and are always present 
in tobacco smoke.
3
  
In addition to nicotine, smokeless tobacco also 
contains numerous toxic substances found in 
tobacco smoke, including TSNA and PAH. The levels of toxic and carcinogenic substances 
differ among products, depending on which type of nicotine plant that is used, the soil where 
it grows, the production and storage process and the presence of nitrate producing bacteria. In 
addition, the tobacco is sometimes flavored or used together with other products which also 
affect the levels of nicotine content and carcinogens.
23
 
Swedish snuff, or snus, contains powered tobacco, water, sodium carbonate, sodium chloride, 
moisturizer and flavoring.
13
 Snus differs from other forms of smokeless tobacco, containing 
considerably lower levels of toxic substances than smoked tobacco and any other ST product.  
Since 2000, Swedish Match has its own quality standard, Gothiatek,
26
 which controls every 
step of the production process, including packaging and storage of snuff.
12
 The tobacco is air-
dried and pasteurized, which decreases the level of TSNA. Gothiatek controls that levels of 
nitrate, TSNA, NMDA (volatile nitrosamine), PAH and heavy metals (cadmium, lead, 
arsenic, nickel and chromium) in Swedish snuff are below WHO recommendations for 
smokeless tobacco.
27
 Swedish snuff is also regulated by the Swedish National Food Agency, 
and production and additive standards are therefore the same as for those for food products.
12, 
28, 29
 American oral moist snuff is different from Swedish snuff regarding toxicity and level of 
harmful substances. Because of different production processes, the levels of TSNA, PAH, 
formaldehydes and metals are considerably higher in American snuff. Mean TSNA in 
Swedish snuff is 1.1ug/g
29
, in comparison to that of American moist snuff with TSNA levels 
ranging from 4.87ug/g to 90.02ug/g tobacco.
30
 
  
Figure 5. Nicotiana tabacum 
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2.6 HEALTH EFFECTS OF SMOKING 
“Smoking is a custom loathsome to the eye, hateful to the nose, harmful to the brain, 
dangerous to the lungs, and in the black, stinking fume thereof nearest resembling the 
horrible Stygian smoke of the pit that is bottomless.” James I of England, A counterblast to tobacco, 
1604 
Smoking is predicted to account for 1 billion deaths in the 21th century. 
31
 Europe and North 
and South America have the highest proportion of smoke related mortality (25 and 17%, 
respectively) because of their long history of smoking.
31
  
There is a causal relationship between smoking and diminished overall health as well as an 
increased risk of all-cause mortality in men and women.
2
 Tobacco smoke has adverse effects 
on almost all organs. Smoking is a risk factor for non-communicable diseases like cancer, 
respiratory problems, cardiovascular disease, periodontitis, cataract and reproductive 
problems. Smoking also increases the risk of attracting communicable diseases like 
pneumonia and tuberculosis.
2
  
Figure 6. Health effects related to smoking 
Source: Adapted from USDHHS 2004, 2006, 2012, 2014 
Note: Each condition presented in bold text and followed by an asterisk (*) is a new disease that has been 
causally linked to smoking in the USDHHS 2014 report. 
Approximately 70% of all lung cancer is attributable to tobacco smoking. Tobacco smoke is 
also associated with oropharyngeal cancer, hepatocellular cancer, cancer in esophagus, 
pancreas, kidney, bladder, colorectal cancer and cervix cancer. Furthermore, the results of 
cancer treatment is poorer in smokers with cancer.
2
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Both active smoking and exposure to second-hand smoking increase the risk of adverse 
cardiovascular effects like atherosclerosis, acute myocardial infarct (MI), stroke, aortic 
aneurysm and sudden cardiovascular death.
2
 
Combustion products in tobacco smoke increase the risk of developing chronic obstructive 
pulmonary disease, COPD, and more than 42% of all COPD is attributable to smoking. There 
is also an increasing risk of pneumonia and exacerbation of bronchitis in smokers with 
COPD. In addition, smoking is also associated with poor asthma control and exacerbation of 
asthma.
2
 
2.7 HEALTH EFFECTS OF SWEDISH SNUFF 
“The Swedish Experience.” Swedish Match 
Sweden has the lowest smoke–related mortality and morbidity in Europe, although the total 
level of tobacco consumption is comparable to the average consumption in Europe.
4
 This is 
explained by the extensive use of snuff among men in Sweden.  
Figure 7. The proportion of mortality attributable to tobacco in European males 
 
Source: Swedish match. Adapted from WHO Mortality Attributable to tobacco, 2012 
Internationally, “the Swedish Experience” is debated by researchers, politicians and public 
health experts, discussing if snuff is to be looked upon as a harm reduction product
32
 in the 
struggle against the smoking related health problems encountered worldwide or as yet 
another tobacco product causing addiction
32, 33
 and contributing to poorer health.
13, 16, 34, 35
   
A few studies have found associations between snuff use and increased risk of pancreatic 
36, 37
 
and esophageal cancer,
38
 but the risk is significantly lower than with smoking.
39
 Compared 
with non-tobacco users, snuff users generally have a slightly poorer cancer outcome, but if 
that is attributable to Swedish snuff or to confounding factors is not clear.
40
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Oral mucosal lesions from snuff use have not been associated with cancer.
41
 In a review, Lee 
et al. argue that the evidence for snuff and risk of cancer is weak.
41
  
There is little evidence that snuff use is associated with increased risk of acute myocardial 
infarct or stroke.
41
 No association has been found between snuff use and hypertension.
41
 
Likewise, safety studies of nicotine replacement therapy have not been associated with 
increased cardiovascular risk.
3
 However, there is growing evidence that snuff use, like 
smoking, is associated with increased insulin resistance and with increased risk of type 2- 
diabetes, and that the risk increases with increasing snuff use.
42, 43
  
2.8 TOBACCO USE AND REPRODUCTIVE HEALTH 
Smoking is associated with a poorer reproductive health in both men and women. The 
Practice Committee of the American Society has stated that 13% of infertility in the US may 
be attributable to smoking.
44
 Studies of snuff use and fertility are lacking. 
Smoking is associated with erectile dysfunction,
2
 decreased production of testosterone in the 
Leydig cells
2
 and an impaired spermatogenesis with DNA damage.
3
 In females, smoking is 
associated with a shortened menstrual cycle, an earlier menopause and subfertility.
2, 3, 44
 
Smoking is also associated with hormonal disturbances, such as elevated levels of follicle 
stimulating hormone (FSH) and decreased progesterone levels.
2, 3
  
Prenatal exposure to smoke has been associated with impaired fertility in adulthood in both 
men and women.
3, 45
 
There is evidence in animal studies that nicotine is involved in the mechanisms behind 
reproductive dysfunction.
46
  Nicotine seems to affect the hypothalamic-pituitary-gonadal 
(HPG) axis, controlling the hormonal balance and the sexual development and function.
3
  
2.9 TOBACCO USE AND NICOTINE EXPOSURE IN PREGNANCY 
”Smoking behavoiur of women differs from that of men….more highly motivated to 
smoke….they find it harder to stop smoking…. women are more neurotic than men… there 
may be a case for launching a female oriented cigarette with relatively high deliveries of 
nicotine…” 1976 research report,  British American Tobacco 
Maternal smoking is still one of the most important preventable risk factors for maternal and 
neonatal health globally. It is associated with adverse fetal and neonatal outcomes with 
increased risk of neonatal morbidity and mortality but also with long-term effects of the 
health of the child.
1
 
The common substance in tobacco smoke and snuff is nicotine, and effects on the health 
caused by nicotine should theoretically be similar between smokers and snuff users. 
However, in the debate about Swedish snuff as a means of smoking cessation and a 
possibility to reduce the smoke related morbidity and mortality, the adverse effects of 
nicotine and use of snuff in pregnancy are rarely discussed. 
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Prevalence of smoking and snuff use in pregnancy 
Comparing data on the prevalence of maternal smoking on a global level is not 
unproblematic, because of the differences in maternal care systems, lack of national statistics 
in many countries, poor coverage of data and different periods in pregnancy when data is 
collected. Most data on tobacco use in pregnancy is based on self-reported information. 
Because of the social stigma related to smoking in pregnancy, there is a risk of 
underreporting of use, leading to misclassification of tobacco use.
47, 48
  
The prevalence of maternal smoking in the US is approximately 15%, with great variation 
between states.
49
 In the US, smoking in pregnancy is most frequent among American Indian/ 
Alaska Natives (26%), followed by non-Hispanics Whites.
49
  
In the European countries, maternal smoking in early pregnancy varies from 5% to 20%.
50, 51
 
As many as 17% smoke in late pregnancy in France and 12% in the UK and Germany.
51, 52
 In 
Eastern Europe, e.g. Poland, Greece and Croatia, the smoking prevalence in pregnancy 
ranges from 12% to 19%.
51
 
Figure 8. The prevalence of smoking during pregnancy in European countries 
 
Source: Smedberg et al., 2014. Published from BMC Pregnancy Childbirth. 
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The prevalence of smoking before pregnancy in Sweden is 13.6%. However, the prevalence 
of smoking in early pregnancy has decreased from almost 30% in the mid-1980’s to 5.5% in 
2014.
6
 The same is true for most Nordic countries except Finland, where the prevalence of 
maternal smoking in early pregnancy is still around 15%.
53
  
Figure 9. The prevalence of maternal smoking in early pregnancy in the Nordic 
countries, 1983–2014 
  
In Sweden, 4.6% use snuff three months before pregnancy, and 1.3% of women use snuff in 
early pregnancy. In late pregnancy, according to the Swedish Medical Birth Register, only 
4% smoke and 0.7% use snuff.
6
 
There are also large regional differences in tobacco habits within Sweden. In the northern 
counties, like Jämtland and Västernorrland, the proportions of smokers and snuff users in 
early pregnancy are similar. In contrast, in the southern part of Sweden, smoking in early 
pregnancy is 8-9%, whereas the prevalence of snuff use is less than 1%. The county of 
Stockholm has the lowest tobacco consumption in the country with only 3.3% smokers and 
1.1% snuff users in early pregnancy.
6
 
Maternal characteristics of tobacco use  
Maternal smoking is associated with low socioeconomic status, low education level, not 
living with the father-to-be, having large number of children and inadequate prenatal care.
6, 49, 
51, 54
 A smoking partner increases the risk of continued smoking in pregnancy, as does a high 
level of pre-pregnancy smoking.
55
 
According to the National Board of Healthcare in Sweden, as many as 16% of women with 
an education of 9 years or less smoked in early pregnancy, in comparison to 1.3% among 
women with more than 12 years of education. Approximately 20% of women below 20 years 
of age smoked in early pregnancy.
6
  
Source: Adapted from Perinatal 
statistics in the Nordic countries, 
THL, 2014 
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Tobacco use and effects on pregnancy and the health of the newborn 
Maternal smoking is associated with pregnancy complications like increased risk of 
spontaneous abortion,
56, 57
 ectopic pregnancies,
3, 45
 placenta dysfunction, placenta previa and 
placenta abruption.
1, 58, 59
 Maternal smoking is also associated with increased risk of 
spontaneous and induced preterm birth, fetal growth restriction, stillbirth and oral cleft 
malformations.
2
  
There is an increased risk of neonatal and infant mortality and morbidity in infants of 
smokers.
1, 2
 Maternal smoking is also associated with increased risk of sudden infant death 
syndrome (SIDS).
1, 2
 
Furthermore, prenatal exposure to smoke has also been associated with long term effects, 
such as respiratory problems and otitis in childhood.
2
 Many studies have also shown 
associations between maternal smoking and behavioral problems in the offspring,
2, 3
 but 
because of residual confounding it is difficult to infer causality. 
In contrast to maternal smoking, snuff use during pregnancy has not been shown to be 
associated with placental dysfunction, such as placenta previa or placental abruption. 
60
 
However, maternal snuff use has been associated with preterm birth
61, 62
 and stillbirth.
60, 63
 
Baba et al. have also shown an association between snuff use in pregnancy and increased risk 
of being born small for gestational age (SGA).
64
 
Spontaneous abortion and ectopic pregnancies 
Spontaneous abortion (SAB) occurs in approximately 12% of all pregnancies and is defined 
as an involuntary termination of pregnancy before 20 weeks of gestation. Most SAB occur 
before the 12
th
 week of gestation.
3
 Maternal smoking and exposure to second-hand smoke is 
associated with increased risk of SAB.
56, 57
 The mechanisms behind the effects of smoking 
are not clear, but placental insufficiency and fetal hypoxia from CO exposure and toxic 
effects of cadmium and cyanide in tobacco smoke have been suggested.
2, 44
  
In ectopic pregnancy a fertilized egg is implanted outside the uterus, usually in the fallopian 
tube. It occurs in 1-2% of pregnancies.
65
 Ectopic pregnancy is a risk factor for maternal 
mortality, subsequent infertility and/or recurrent ectopic pregnancies.
65
 
The etiology of ectopic pregnancies is not fully understood but seems to involve motility of 
the fallopian tubes. The embryo remains within the fallopian tube because of structural or 
functional impairment of the tube, preventing implantation to occur.
2, 65
 Suggested risk 
factors are history of previous ectopic pregnancy or SAB, sexually transmitted disease or 
surgical procedures affecting the fallopian tubes.
2, 65, 66
 
The Surgeon General Report, 2014 concludes a causal relationship between smoking and 
ectopic pregnancy. There is evidence from animal studies that nicotine is playing a role in the 
mechanism behind ectopic pregnancy.
2, 66
 There is a lack of knowledge about the association 
between snuff use and SAB or ectopic pregnancy.  
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Preeclampsia 
Preeclampsia is a syndrome of reduced organ perfusion caused by vasospasm and endothelial 
dysfunction of the placenta, clinically defined as marked hypertonia and proteinuria, with an 
onset after 20 weeks of gestation.
2
 Preeclampsia is a major cause of maternal and fetal 
mortality and morbidity globally and is associated with fetal growth restriction, stillbirth and 
placental abruption. It affects 3-7% of pregnant women.
67
  
A two-stage model in the development of the disease is often discussed, where the first stage 
is characterized by defect implantation and formation of the placenta, leading to a hypoxic 
and dysfunctional placenta, inducing inflammation and endothelial damage. This results in 
the symptoms seen in the second stage with elevated blood pressure and proteinuria.
67
  
Maternal smoking has a substantially protective effect and decreases the risk of developing 
preeclampsia.
68
 However, if preeclampsia develops in smokers, the rates of adverse outcomes 
are increased substantially, which may occur as a result of synergistic effects of smoking and 
preeclampsia on the feto-placental circulation.
69
 Snuff use does not protect against 
preeclampsia,
70, 71
 implying that combustion products, such as CO with vasodilative 
properties, and not nicotine, are involved in the underlying protective mechanism. CO also 
reduces levels of anti-angiogenic protein soluble fms-like tyrosine kinas (sFlt-1), which in 
animal models initiate all symptoms of preeclampsia. Smokers have lower levels of sFlt-1 
than nonsmokers.
2
  
Placenta previa and placental abruption  
Maternal smoking is associated with placenta dysfunction and antenatal bleeding, such as 
placenta previa and placental abruption, and the relationship is dose-dependent.
3, 58
 The 
suggested mechanisms of placenta previa are related to chronic ischemia and hypoxia and 
consequent enlargement of placenta.
3
  
The origin of placental abruption is multifactorial but related to placental dysfunction.
72
 
Potential risk factors are advanced maternal age, multiparity, previous placental abruption, 
hypertensive disorders, thrombophilia, previous cesarean section, trauma and uterine 
infections. Suggested underlying causes of abruption are vessel fragility and vascular 
malformation and impaired trophoblastic transformation.
3
 Smoking has been proved to 
interfere with transformation of the spiral arteries and the thickening of the villous membrane 
in the placenta.
3
  
Smoking-related placental abruption has been observed to be related to decidual necrosis at 
the periphery of the placenta, microinfarcts, atheromatous/fibrinoid changes in the placenta 
as well as with hypovascular and atrophic villi.
69, 73
 Hypoxic changes, due to reductions in 
blood flow to the uteroplacental-fetal unit associated with cigarette smoking, may lead to 
placental infarcts and increased capillary fragility, in turn leading to arterial rupture and, 
subsequently, to placental abruption.
72, 73
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Smoking is supposed to impair collagen synthesis in placenta and induce inflammation in 
placental vessels.
1, 73
 Studies of consecutive pregnancies show remaining but decreased risk 
when women stop smoking between pregnancies.
59
  
Preterm birth 
Preterm birth is defined as live birth before 37 weeks of gestation. Extremely preterm birth is 
defined as birth <28 weeks of gestation, very preterm birth 28 to <32 gestational week and 
moderately preterm birth 32 to <37 weeks of gestation. The highest morbidity and mortality 
is among the most preterm infants, born before 28 weeks of gestation. 
More than 15 million babies are born preterm every year, and the incidence is increasing in 
most countries.
74
 Preterm birth is the leading cause of perinatal morbidity and mortality in the 
developed countries, with an incidence of 11.1% globally.
75, 76
 In the US, 12% of all babies 
are born preterm.
76
 In Europe, preterm birth rates vary between 5-10%.
50
 In Sweden, 
approximately 6% of all live born births are preterm.
6
 Of live born singleton births in 
Sweden, 4.4% are born before 37 weeks; 0.2% are born extremely preterm, 0.6 % very 
preterm and 3.6% moderately preterm.
6
  
Figure 10. Definition of preterm birth according to WHO 
 
Preterm birth can be divided in spontaneous preterm birth (including spontaneous labor with 
intact membranes and spontaneous preterm premature rupture of membranes, PPROM) and 
induced preterm birth, i.e. induced labor or cesarean delivery for fetal or maternal 
indications.
77
  
The cause of spontaneous preterm birth is multifactorial. Maternal history of preterm birth is 
a strong risk factor and suggested to be generated by the interaction of transgenic and 
environmental risk factors.
76
 The role of ethnicity in preterm birth has been discussed and a 
variation in gestational length for different ethnic groups has been suggested; babies of 
African ancestry tend to be born earlier than babies of Caucasian ancestry.
76
 
Previous preterm birth, multiple pregnancies, IVF pregnancies, intrauterine infection or 
inflammation and chronic diseases, such as hypertension, diabetes and thyroid disease are all 
associated with preterm birth.
76, 78
 Preeclampsia, placental abruption, fetal growth restriction, 
maternal chronic disease and obesity are associated with medically indicated preterm birth.
77
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Maternal smoking has been casually related to preterm birth
1, 3, 45
 and has been associated 
with both spontaneous and induced preterm birth.
79
 The pathophysiological mechanisms are 
not clear, but smoking is associated with placental dysfunction, placenta previa and placental 
abruption as well as with fetal growth restriction, all associated with preterm birth.
2, 3
  
Snuff use is also associated with preterm birth.
61, 62
 However, snuff use is not associated with 
placental bleedings, placenta previa or placental abruption and the increased risk of impaired 
growth is moderate,
64
 implying a different causal pathway for snuff and preterm birth than for 
that of tobacco smoke. The common substance in snuff and smoking is nicotine. In addition, 
tobacco smoke also contains numerous combustion products which may affect the risk of 
preterm birth, possibly through placenta dysfunction and subsequent fetal growth restriction. 
Nicotine has vasoconstrictive properties, reducing the utero-placental blood flow
80
 and may 
also affect the formation of the placenta in early pregnancy. Snuff use is a risk factor for 
early, but not late clinical stages of preeclampsia, suggesting that nicotine affects the 
formation of placenta,
71
 which may play a role in the mechanisms behind preterm birth. 
In addition, both combustion products of smoke and nicotine are supposed to affect the 
immune system,
81
 and inflammation is a plausible explanation behind the increased risk of 
preterm birth. Inflammation and/or infection are known risk factors of preterm birth.
78, 82
  
Fetal growth restriction 
Both maternal smoking and maternal exposure to secondhand smoke are regarded causally 
related to fetal growth restriction.
2
 A consistent finding is that infants of smoking mothers 
weigh 150-200 g less than infants of non-tobacco users.
3
 Maternal smoking is also associated 
with SGA births, and the association is dose-dependent and correlated with maternal cotinine 
levels.
2, 3
 How smoking affects fetal growth is not clear, but placenta dysfunction is believed 
to play a role. Maternal smoking is related to disturbances in the transformation of the spiral 
arteries and the thickening of the villous membrane forming the placenta, leading to placental 
dysfunction.
3
 In addition, CO induces fetal hypoxia by binding to hemoglobin and inhibiting 
oxygen release. Nicotine is vasoconstrictive and has been supposed to decrease utero-
placental blood flow with subsequent reduction in the delivery of oxygen and nutrients to the 
fetus.
80
  
Animal studies of prenatal nicotine-exposure and effects on birth weight show conflicting 
results, but the majority show that nicotine impairs fetal and neonatal growth.
83
 If nicotine has 
a major impact on fetal growth, smokeless tobacco and Swedish snuff should also be 
associated with low birth weight and SGA births, but most studies on snuff use or smokeless 
tobacco in pregnancy have shown very modest or no association with low birth weight.
70, 84, 85
 
However, Baba et al. found an association between snuff use and slightly increased risk of 
SGA birth, 1.38 OR (95% CI: 1.01-1.88), in comparison with that of nonusers.
64
 The risk 
associated with smoking was higher, 3.21 OR (95% CI: 3.02-3.40).
64
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In addition, for women who had stopped using snuff before the antenatal booking, there was 
no increased risk of SGA birth, whereas women who stopped smoking before the antenatal 
booking had a lower, albeit increased risk of SGA birth compared to that of nonusers, OR 
1.82(1.65-2.01).
64
 Gupta et al. have shown decreased birth weight with use of mishri in 
pregnancy.
86
 However, mishri and many other ST products contain numerous potentially 
toxic substances associated with low birth weight, such as PAH.
3, 23
 The socio-demographic 
and cultural differences also make comparisons difficult to interpret.  
To conclude, in humans the effect of nicotine on fetal growth seems to be modest in 
comparison to the effect of CO and other combustion products in smoke. Nicotine and CO 
and other combustion products may have synergistic effects on growth, explaining why 
smoking has a greater impact on growth than snuff use. 
Stillbirth and neonatal and infant mortality 
The estimated global stillbirth rate was 18.4/1000 live-born infants in 2015 (fetal age ≥28 
weeks gestational weeks).
87
 In Sweden, the incidence of stillbirth (fetal age ≥22 gestational 
weeks) is 4/1000 live born infants and the neonatal mortality is 1.5/ 1000 live-born babies.
6
 
As a consequence of a changed definition of stillbirth from fetal age ≥28 weeks to fetal age 
≥22 weeks, the incidence of stillbirth in Sweden increased in 2008. 
Figure 11. Incidence of stillbirth and neonatal mortality, 1974 -2014 
 
Source: Adapted from National Board of Health: Pregnancies and Deliveries, 2015 
The majority of stillbirths are preterm, but the risk of stillbirth increases with increasing 
gestational age. Risk factors for stillbirth are chromosomal and fetal abnormalities, high 
maternal age, obesity, intrauterine growth restriction, preeclampsia and placental bleedings.
88, 
89
 Both maternal smoking and use of snuff in pregnancy are associated with an increased risk 
of stillbirth.
63
 
  27 
Figure 12. Risk of stillbirth per 10 000 pregnancies by gestational week 
 
Maternal smoking is primarily associated with preterm stillbirth. Several studies have shown 
that the risk of stillbirth is mediated through increased risk of placental bleeding and 
intrauterine growth restriction.
88
 Wikström et al. have shown that when women with 
preeclampsia, placental bleeding and/or small for gestational age deliveries were excluded 
from analysis, the smoking-related risk of stillbirth was attenuated, whereas it remained 
among snuff users.
60
 Contrary to maternal smoking, snuff use in pregnancy is not associated 
with placental bleeding, and only a modest association between snuff use in pregnancy and 
fetal growth restriction has been found.
64
 Importantly, women who stopped smoking or using 
snuff in early pregnancy were not at increased risk of stillbirth compared to that of non-
tobacco users.
63
  
There is evidence that defect early placentation increases risk of stillbirth.
90
 Nicotine possibly 
affects early placentation.
71
 These findings suggest that nicotine is involved in the underlying 
mechanism of stillbirth, but in smokers combustion products may also play a role. In 
addition, Gupta et al. have shown increased risk of stillbirth after prenatal exposure to 
smokeless tobacco.
91
 
In contrast to maternal smoking, snuff use is not associated with increased risk of early 
neonatal mortality.
63
 However, Baba et al. showed that when adjusting for gestational age, the 
risk of early neonatal mortality decreased, suggesting that the early neonatal mortality is 
mediated through preterm birth. Maternal smoking is also associated with increased infant 
mortality, which is believed to be mediated by the increased risk of preterm birth and growth 
restriction
92
 as well as with the increased risk of sudden infant death syndrome. 
54
 
Source: Wikström et al. 
Epidemiology, 2010. 
Published with kind 
permission from Elsevier. 
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Sudden Infant Death Syndrome 
Sudden infant death syndrome, SIDS, is defined as a sudden unexplained death of a child 
below one year of age. A number of risk factors related to SIDS have been identified, such as 
prone position of sleep, bed sharing and overheating.
93
 Since 1992, when the 
recommendation for non-prone sleeping position was launched, there has been a considerable 
decrease in SIDS cases.  
Figure 13. Factors associated with increased risk of Sudden Infant Death Syndrome 
 
Source: Trachtenberg et al., Pediatrics. 2012 Apr; 129(4): 630–638. 
A causal relation between maternal smoking, postnatal exposure to tobacco smoke and SIDS 
has been established.
2, 3
 There is almost a threefold increased risk of SIDS among infants 
exposed to smoke prenatally, and the proportion of SIDS cases attributable to tobacco smoke 
is 23.2 according to Dietz et al., 2010.
54
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Figure 14.The incidence of SIDS and correlation with preventive recommendations 
 
Source: Adapted from the National Board of Health and Welfare: Minska risken för plötslig spädbarnsdöd, 2014  
SIDS is associated with disturbed cardiorespiratory control
94
 with blunt response to hypoxia 
and an impaired arousal.
95, 96
 In the postnatal period, the cardiorespiratory system goes 
through maturation, which is a critical period for managing hypoxic stress, explaining why 
most cases of SIDS occur in this period.
94, 97
 
Maternal smoking is associated with disturbed cardiorespiratory control, such as neonatal 
apneas and impaired arousal.
98-101
 Several studies on prenatal nicotine exposure in animal 
studies have shown disturbances in the autonomic nervous system and disturbed 
cardiorespiratory control,
102, 103
 
104
 which suggests that nicotine is involved in the mechanisms 
behind the smoking- related risks of SIDS. 
3
 
Oral cleft malformation 
With an incidence of 1.7/1000 live-born, oral cleft malformations is one of the most common 
malformations.
105
 Non-syndromic orofacial clefts include cleft lip, cleft lip and palate and 
isolated cleft palate. Oral cleft lip, with or without cleft palate (CL/P) and isolated cleft palate 
(CP) are embryological distinct entities with different epidemiological characteristics.
106
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Figure 15. Schematic presentation of different types of non-syndromic orofacial clefts 
 
(A) Cleft lip and alveolus. (B) Cleft palate. (C) Incomplete unilateral cleft lip and palate. (D) Complete unilateral 
cleft lip and palate. (E) Complete bilateral cleft lip and palate. 
Source: Mossey et al., Lancet 2009. Published with kind permission from Elsvier. Reprinted with permission 
from:Shaw WC. Orthodontics and occlusal management. Oxford: Butterworth-Heinemann, 1993 
The etiology of oral cleft malformations is largely unknown and multifactorial, with large 
ethnic and genetic variation. Proposed environmental risk factors are maternal smoking, 
alcohol consumption and lack of vitamins, such as folic acids and zinc.
105-107
  
CL/P and CP occur in the early trimester in the fourth to eighth gestational weeks as the result 
of disturbed fusion of the facial prominences. The earlier the interruption of fusion occurs, the 
greater the defect.
105
 Moreover, CL/P has a different pathophysiological origin than CP. Cleft 
lip, with or without cleft palate is the result of interrupted fusion of the primary palate, while 
isolated oral cleft is the result of inhibited formation of the secondary palate.
105, 106
 
Maternal smoking has been causally related to maternal smoking. There are also findings 
suggesting an interaction between maternal smoking and genetic polymorphism.
108-110
 
Maternal smoking is also associated with insufficient levels of vitamin C and zinc.
111-113
 
Vitamin deficiency is supposed to influence risk of oral cleft malformations,
105
 and a few 
studies have found interactions between maternal smoking, vitamin supplements and risk of 
oral cleft malformations.
114
 
Animal studies and in vitro studies suggest that nicotine inhibits the fusion of the facial 
prominences.
115-117
 A Danish Medical Birth Register study found an association between 
NRT and oral cleft malformations and limb defects.
118
 However, compliance with NRT in 
pregnancy is poor;
11
 women continue to smoke using NRT. Thus, the results should be 
interpreted with caution. 
Congenital malformations 
Maternal smoking is not strongly associated with malformations, nor is nicotine in animal 
studies. Hackshaw et al., 2011, concluded in a meta-analysis that maternal smoking was 
associated with the following congenital abnormalities in addition to oral cleft malformations: 
clubfoot, gastroschisis and atrial septal heart defects, anal atresia, craniosynostosis, limb 
reduction defects and cryptorchidism.
2, 119
 These findings were supported by a later Danish 
register based cohort study. 
120
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Table 1. Summary of a systematic review of maternal smoking during pregnancy 
and its relationship with specific congenital malformations. 
Outcome 
No. of studies 
published, 1959-2010 
OR (95% CI) 
Orofacial clefts 38 1.28 (1.20-1.36) 
Clubfoot 12 1.28 (1.10-1.47) 
Gastroschisis 12 1.50 (1.28-1.76) 
Congenital heart defects 25 1.09 (1.02-1.17) 
Craniosynostosis 5 1.33 (1.03-1.73) 
Anorectal atresia 7 1.20 (1.06-1.36) 
Source: Adapted from Hackshaw et al., 2011 
Long term effects of tobacco use in pregnancy 
Maternal smoking is associated with increased risk of asthma and respiratory problems in 
children.
2, 3, 121, 122
 Furthermore, smoking in pregnancy is associated with overweight, 
hypertension and type-2 diabetes in the offspring.
123, 124
 Maternal smoking is related to 
growth restriction, which is a known risk factor for hypertension, type-2 diabetes and obesity 
later in life.
125-128
 Many studies have found associations between maternal smoking and 
neurobehavioral disorders.
2, 129
 However, this is difficult to study because of the 
socioeconomic and psychiatric confounding related to nicotine addiction. Findings in animal 
studies of nicotine and neurobehavioral disturbances support the findings in human 
epidemiological studies.
130, 131
 
Tobacco cessation in pregnancy 
"To cease smoking is the easiest thing I ever did. I ought to know because I've done it a 
thousand times." Mark Twain 
The majority of women stop smoking before the antenatal booking without any professional 
guidance.
132
 However, almost 50% continue smoking in pregnancy.
49
 A smoking partner, a 
high level of smoking prior pregnancy and multiparity are the most important predictive 
factors of continued smoking in pregnancy.
133
 Although the proportion of smoking in 
pregnancy is higher in young women, the quitting rate during pregnancy is also higher among 
teenage mothers.
134
  
Nicotine replacement therapy has not proved efficient in randomized control studies, because 
adherence to medication was low.
11, 135
 Psychosocial clinic-based interventions in the prenatal 
care setting have also shown modest results on cessation rates.
132
 According to the Surgeon 
General 2014, there is evidence of tobacco control policies having effect on maternal smoke 
cessation.
2
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2.10 NICOTINE 
Nicotine binds to nicotine-acetylcholine receptors (nAChR), which are present at 
neuromuscular junctions, in the peripheral and central nervous system and also in many non-
neural cells in muscle, skin, lung and pancreas. 
136
 
 
Figure16. Nicotine molecule and a schematic presentation of the nicotine-acetylcholine 
receptor.  
The nicotine-acetylcholine receptor (nAChR) consists of five subunits forming a pore in the 
cell membrane and is a ligand-gated ion channel that mediates fast neurotransmission. The 
receptor consists of a combination of four related, but genetically and immunologically 
distinct, subunits forming a pentamer.  
The variation of different types of subunits, combinations of subunits and the functional 
properties of different subunits explain the diversity of the physiological processes that the 
nAChR is involved in. The nAchR has metabolic and endocrine effects as well affecting the 
immune and nervous system. Furthermore, nAChR is also involved in control of endothelial 
function.
137
 
Table 2.Physiological effects of nicotine 
Cardiovascular Endocrine and 
metabolic 
Immune system CNS-behavioral 
effects 
Increased heart rate, 
cardiac contractility,  
and blood pressure 
Adrenocorticotropic 
hormone, cortisol 
Catecholamine release 
Immune suppressant Relaxation or arousal 
Cutaneous and systemic 
vasoconstriction 
Release of growth 
hormone, vasopressin,  
Affect T-cell signalling Enhanced 
concentration 
Increased muscle blood 
flow 
 Immune modulatory 
effects on the central 
nervous system by: 
1) the HPA axis 
2) direct effects on the 
autonomic nervous 
system. 
Appetite suppression 
Inhibition in prostacyclin 
synthesis, which affects 
endothelial cells and 
Platelet activation. 
  Alertness 
Source:Adapted from Benowitz et.al.1988 
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Pharmacokinetics of nicotine 
Free nicotine, i.e. the non-ionized form of nicotine, easily passes cell membranes, including 
oral mucosa, pulmonary tissue, the blood-brain barrier, placenta and other tissues. It 
accumulates in breast milk
138-141
 and amniotic fluid.
142
 Nicotine is a weak base and the 
proportion of non-ionized nicotine increases with increasing pH-value. Oral moist snuff is 
therefore alkalized to facilitate the absorption of nicotine. 
During cigarette smoking, nicotine reaches the brain within 10-20 seconds, with a peak 
plasma-concentration in 5 minutes.
136
 During snuff use, nicotine is absorbed more slowly, but 
plasma-concentration peaks are similar to that of smoking. Whereas the plasma concentration 
of nicotine falls rapidly after smoking, the nicotine plasma-concentration of snuff users 
reaches a plateau after 30 minutes, and nicotine levels slowly decline after 1-2 hours. It has 
been speculated that the continued release of nicotine, also after use of oral snuff, comes from 
the mucus membranes.
143, 144
  
NRT, such as gums and patches, has a substantially slower absorbance and lower peak 
plasma–concentrations, which is why the addictive potential is low.145 
Figure 17. Plasma nicotine concentration from different sources of nicotine 
 
Source: Adapted from Henningfield 1995 and Molneux, 2004. 
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Only a small amount of the nicotine in the cigarette or pouch of snuff is absorbed. Smoking 
behavior affects nicotine absorption through inhalation volume, number of puffs and number 
of covered ventilation holes in the filter of the cigarette.
146, 147
 The amount of nicotine 
absorbed by the body during snuff use depends on how long the pouch is kept in the mouth 
and the properties of the snuff, such as the total nicotine content and the pH-value. The rate of 
absorbance and metabolism also varies substantially between individuals.
136
  
As mentioned above, the pattern of tobacco use also affects nicotine plasma-levels. Whereas 
smoking gives high peaks of nicotine intermittently during the day, many snuff users have a 
pouch of snuff under the lip throughout the day which leads to a continuously high level of 
nicotine. 
Nicotine metabolism 
Nicotine is metabolized in the liver, primarily by cytochrome 2A6. It has a half-life of 2 
hours and is subsequently eliminated by the kidneys. The primary metabolite of nicotine, 
cotinine, has a half-life of 18 hours and is the most frequently used biomarker of nicotine 
exposure.
136
 There are major individual differences in nicotine and cotinine metabolism 
which are believed to affect the risk of addiction. Thus fast metabolizers appear to have a 
higher risk of addiction than slow metabolizers.
145
 
Women have a higher metabolism of nicotine and cotinine than men. Women using oral 
contraceptives and pregnant women have a higher nicotine metabolism than non-pregnant 
women, not using oral contraceptives.
136
 Nicotine metabolism is also elevated in pregnancy, 
which leads to a half-life of cotinine of 8-9 hours.
142, 148
 In contrast, the nicotine metabolism 
in newborns is slower than in adults, with a half-life three times longer in infants. The 
cotinine metabolism seems to be the same as in adults, though.
136
 This might explain why 
nicotine, which easily passes placenta, seems to accumulate in amniotic fluids.
80
 Luck et al. 
found that fetal concentrations in cord blood were 15% higher than maternal levels at the time 
of delivery.
139
  
Nicotine also easily passes into breastmilk, leading to a milk-to-maternal plasma ratio of 
2.9.
141
 Nicotine in breastmilk is swallowed by the infant, and there is insufficient knowledge 
about absorption of nicotine in the gastrointestinal tract of the infant.
141
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Effects of nicotine during development 
The effects of nicotine during development are very different from the effects in the adult. 
The nAChRs is present very early in the developing human fetus, as early as gestational week 
4-5, and acetylcholine plays an important role in brain and lung maturation. Nicotine is  a 
potent neuroteratogen and binds to nicotinic AChRs in the developing brain and lung, 
inducing apoptosis and affecting cell programming.
104
 
129, 131
 
Prenatal nicotine exposure is also known to affect the cardiovascular, the endocrine and the 
immune system, inducing structural and even transgenetical changes that may have effect 
also in adulthood.
46, 149-153
 In animal studies, prenatal nicotine-exposure induces lung 
hypoplasia, emphysema-like changes, such as decreased elastin and increased collagen 
synthesis in vascular endothelial cells and lung parenchyma.
102
 The morphological changes 
are associated with increased airway resistance and hyper reactivity, observed in children 
exposed to maternal smoking, suggesting that nicotine is involved in the development of 
asthma and lung disease.
102
 In addition, nicotine has effects on the nervous system and on the 
developing brain at doses that have no impact on fetal growth.
104
 This is important in the 
discussion of NRT use in pregnancy.
131
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3 EPIDEMIOLOGICAL TERMINOLOGY 
Bias is a systematic error in a study. Selection bias in a study stems from how study subjects 
are collected and/or from factors that influence study participation. Information bias or 
misclassification arises when there is a systematic error in the collecting of information. 
Misclassification of subjects of an exposure or outcome can be divided in differential and 
non-differential misclassification. The exposure bias is non-differential if the 
misclassification is unrelated to the outcome. If the exposure misclassification is related to the 
outcome, it is a differential misclassification. A differential misclassification is associated 
with under- or over -estimation of the effect on the outcome, whereas a non-differential 
misclassification tends to dilute the effect of the exposure on the outcome, resulting in a bias 
towards the null. Recall bias is a differential misclassification bias, where the exposure 
information is misclassified differentially for those with and without disease. 
Confounding is a type of bias, that obscures or distorts the result of an association. A 
confounding factor is associated with both the exposure and the studied outcome. It may 
cause the outcome or be a proxy for the outcome but not be an effect of the outcome. A 
confounder is not an intermediate in the causal pathway between the exposure and the 
outcome.  
                          
Internal validity describes if the study or a test accurately measures what it is supposed to 
measure, which means lack of systematic errors such as bias, misclassification or 
confounding. 
External validity or generalizability describes if the study is representative beyond the 
study population and if the result of the study is applicable not only to the study population, 
but also to the reference population. 
Sensitivity is defined as the proportion classified by the test as having the disease among all 
in the population having the disease. 
Specificity is defined as the proportion classified by the test as not having the disease among 
all in the population without the disease. 
Positive predictive value is the probability of the disease among those with a positive test. 
Negative predicted value is the probability of no disease among those with a negative test. 
Receiver operating characteristics curve, ROC, describes the relationship between the 
sensitivity and specificity of a test and is used to decide the cut-off values for an optimal 
combination of sensitivity and specificity for a test. 
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4 AIM 
The overall aim of this thesis was to study prenatal nicotine exposure, in the form of oral 
moist snuff and smoking, and its effects on the health of the newborn. The general research 
question was to investigate if it is safe to use snuff in pregnancy, and if cessation of snuff use 
or smoking during pregnancy influences the possibly adverse risks on the health of the 
newborn.  
Specific research objectives: 
Study I  
 To investigate if maternal smoking or snuff use is associated with neonatal apnea.  
Study II  
 To study if smoking or snuff use in pregnancy is associated with increased risk of oral 
cleft malformations. 
 To study if cessation of snuff use or smoking in early pregnancy influences the risk of 
oral cleft malformations in the newborn. 
Study III 
 To assess the relationship between maternal smoking or snuff use and extremely 
preterm birth.  
 To study if cessation of snuff use or smoking influences the risk of extremely preterm 
birth. 
 To investigate the association between tobacco use and spontaneous and medically 
indicated onset of preterm delivery. 
Study IV 
 To validate prospectively self-reported questionnaire data on snuff use in late 
pregnancy by quantifying cotinine in maternal urine and newborn meconium. 
 To validate self-reported information on tobacco use in the Swedish Medical Birth 
Register in late pregnancy by cotinine in maternal urine and newborn meconium. 
 To study if the levels of cotinine can be used to identify mothers with high nicotine 
intake. 
 To investigate the relation between cotinine levels and neonatal birth characteristics, 
such as birth weight, length, head circumference and gestational age. 
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5 METHODOLOGICAL CONSIDERATIONS 
The methods used in the individual papers are described in each paper and will not be 
explained in detail in this chapter.  
5.1 DATA SOURCES 
This thesis is predominately based on population-based studies in the Swedish Medical Birth 
Register (paper I-III) with linkage to other data sources from the National Board of Health, 
such as the Patient Register
154
, the Education Register and the Total Population Register held 
by Statistics Sweden.
155, 156
  
Study IV is a validation study of prospectively collected self-reported snuff use during 
pregnancy by the biomarker cotinine in maternal urine and in the meconium of the newborn. 
In addition, Medical Birth Register data for the cohort is linked to the cohort data. 
The Medical Birth Register and other registers 
The Swedish Medical Birth Register (MBR) was started in 1973 and is a population-based 
register that contains data on more than 98% of all births in Sweden, including maternal 
characteristics (demographic data, information on reproductive history and tobacco habits) 
and information on pregnancy, delivery and the neonatal period. Information on smoking in 
early pregnancy has been recorded since 1982, whereas tobacco use in late pregnancy was 
added in 1991. Snuff use was not reported to the MBR until 1999.  
Data on tobacco use is based on prospectively collected self-reported information obtained by 
midwives at the antenatal booking in early pregnancy and in week 32. Tobacco use is 
categorized as no tobacco use, maternal smoking 1-9 cigarettes/day or >=10 cigarettes/day 
and snuff use (yes/no).
6
 
Maternal diseases, complications during pregnancy or delivery and neonatal complications 
and diagnoses are classified according to the Swedish version of the International 
Classification of Diseases (ICD) system and reported at discharge from the delivery hospital.  
Sweden has many other registers, such as the Register on Congenital Malformations, the 
Swedish Cancer Register, the National Cause of Death Register, the National Patient Register 
and the Prescribed Drug Register held by the National Board of Health.
154
 Through the 
unique personal identification number (PIN), several registers and other data sources held by 
Statistics Sweden,
156
 such as the Education Register, the Total Population Register and the 
Multi-Generation Register can be linked together.
155, 157
 
The National Patient Register contains nationwide information on diagnoses and procedures 
and can be divided into the Inpatient Register, with coverage since 1987, and the Outpatient 
Register, with information on all hospital out-patient care since 2001.
154
 Since 1997, both the 
MBR and the National Patient Register diagnoses are classified according to the 10
th
 revision, 
ICD-10. 
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Validation of the Swedish Medical Birth Register 
Since the start of the register in 1973, the MBR has been modified and variables added on 
several occasions, 1982, 1990, 1994 and 1998.
158
 The MBR has been validated according to 
quality and coverage of data several times
159
, the latest in 2002, and has been proved reliable 
with high coverage and data quality on most variables.
158
 Smoking in early pregnancy has 
been missing in 4-9% throughout the years. However, smoking in late pregnancy had until 
2000 a high percentage of missing information and was not useful in research.
158
 According 
to the National Board of Health and Welfare, there was 4-5% missing information on 
smoking and snuff use prior pregnancy, in early pregnancy and in late pregnancy in the MBR 
2014.
6
 Information on drug and alcohol use in pregnancy is of poor quality. 
Missing data on diagnoses of infants who have been transferred between hospitals and 
neonatal wards is still a problem.
158
 Linkage to the Congenital Malformation Register, the 
Hospital Discharge Register or the National Patient Register can be necessary to ascertain 
certain diagnoses in epidemiological studies.
158
 
5.2 STUDY DESIGN AND STUDY POPULATION, PAPER I-III 
 In paper I-III, tobacco exposure in the Medical Birth Register in early pregnancy was 
studied. In paper I, tobacco exposure was categorized as nonuser, snuff user, smoker 1-9 
cigarettes/day and smoker ≥ 10 cigarettes/day.  
Figure18. Schematic presentation of the study designs in paper I-III 
 
What differed in the study design of papers II and papers III from paper I was the 
categorization of tobacco use. In paper II and paper III, tobacco use was categorized as: no 
use (i.e. no use three months prior pregnancy and in early pregnancy); stopped using snuff 
(i.e. snuff use three months before pregnancy but not in early pregnancy); snuff use (i.e. snuff 
use three months before pregnancy and in early pregnancy) and stopped smoking (i.e. 
smoking three months before pregnancy but not in early pregnancy); and smoking (i.e. 
smoking three months before pregnancy and in early pregnancy).  
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ICD-10 codes 
For diagnoses of neonatal apnea and oral cleft malformations ICD-10 codes were used.  
The American Association of Pediatrics
160
 has defined infant apnea as “an unexplained 
episode of cessation of breathing  for 20 seconds or longer, or a shorter respiratory pause 
associated with bradycardia, cyanosis, pallor and/or marked hypotonia.” Neonatal apnea 
unspecified was defined by the following ICD-10 codes: P 28.2 (“cyanotic attack”), P28.3 
(“sleep apnea”) and P28.4 (“other apnea of the newborn”). Sleep apnea was also analyzed 
separately as ICD-10 code P 28.3. 
Oral cleft malformation was defined by the ICD- 10codes Q35-37. The different subtypes of 
oral cleft malformations were analyzed separately, as cleft lip with or without cleft palate 
(ICD-10 codes Q36 and Q37) and isolated oral cleft (ICD-10 Q35). 
In paper II, the Patient Register was linked to the Medical Birth Register to ensure adequate 
coverage on congenital malformation diagnoses. 
Inclusion and exclusion criteria 
Exclusion criteria for all papers were missing information on tobacco use and dual use (snuff 
use and smoking). In the adjusted models missing data on co-variates was also excluded.  
Only mothers of live-born infants were included in the studies I and III. In paper II and paper 
IV both singleton and multiple births were included. 
In paper I, only mothers born in the Nordic countries were included.  
In paper IV, smokers and dual users were excluded from the study. 
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Confounders and intermediate variables 
In paper I-IV, co-variates were chosen because of their association with the exposure and the 
outcome in previous literature. Possible confounders were adjusted for in the adjusted 
analysis.  
BMI is defined as: body weight/height 
2
. Body mass index, BMI, was not adjusted for in 
paper I and paper II despite being a possible confounder associated with both exposure and 
outcome. There is a large number of mothers with missing information on the BMI variable 
in the MBR. When BMI was adjusted for in the regression model without affecting the 
estimate, BMI was not considered a confounder and was left out of the final analysis. In 
paper IV, maternal education and mother’s country of birth were not possible to obtain. 
 
 
  
Table 3. Maternal and birth characteristics used as co-variates in the different 
studies 
Maternal and birth 
characteristics 
Study I  Study II Study III Study IV 
Apnea Oral Cleft 
Malformation 
Preterm 
birth 
Neonatal 
growth 
characteristics 
Maternal age x x x x 
Height x    
BMI   x x 
Parity x x x x 
Cohabitant with father-to-be  x x x x 
Education x x x  
Pre-pregnancy diabetes  x   
Preeclampsia  x   
Mother’s country of birth  x x  
Cesarean Section x    
Small-for-gestational age x    
Gestational age x   x 
Gender x x   
Single or multiple pregnancies  x   
 42 
5.3 STUDY DESIGN AND STUDY POPULATION, PAPER IV 
Self-reported snuff use in pregnancy has not been validated previously. The objective with 
this study was to study the accuracy of self-reported snuff use but also to validate the data on 
snuff use in the Medial Birth Register. 
Between 2005 and 2011, women were asked to participate in a prospective cohort study of 
snuff use during pregnancy. Antenatal clinics in seven counties in Sweden (Jämtland, 
Västernorrland, Västerbotten, Stockholm, Gotland, Gävleborg and Dalarna), chosen by their 
high prevalence of snuff use, took part in the study.  
Inclusion occurred at the antenatal booking, and tobacco use was categorized as no use, snuff 
use or smoking. Only nonusers and snuff users were analyzed further. 
Figure 19. Schematic presentation of the study design, paper IV  
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Figure 20. Schematic presentation of the study population 
 
Self-reported snuff use through questionnaires 
The participants were asked to report their tobacco use through questionnaires at antenatal 
booking, in late pregnancy and immediately after birth. The participants self-reported daily 
use of tobacco for every gestational week, including brand of tobacco used, use of nicotine 
replacement therapy (NRT) and exposure to second-hand smoke (SHS). Snuff use was 
reported as number of pouches/day each gestational week and categorized as follows: no use, 
1-2, 3-4, 5-6 or >7 pouches/day. See Appendix A 
Self-reported snuff use registered in the Medical Birth Register 
We obtained information from medical records from the antenatal and delivery clinics on the 
participants and data from the Medical Birth Register (MBR). To assess if the study 
population was representative of the population, we also obtained data from the MBR for all 
births the corresponding years and geographic regions. As mentioned previously, tobacco use 
in the MBR was categorized as no use, snuff use, smoking 1-9 cigarettes/day and smoking 
>=10 cigarettes/day. 
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Analysis of cotinine 
Maternal urine cotinine was collected in gestational week 32. In addition, cotinine in the 
meconium of the newborn was analyzed. 
To determine cotinine in urine and meconium, a procedure based on high-performance liquid 
chromatography tandem mass spectrometry (HPLC-MS/MS) was used.
161
 Meconium was 
first extracted with methanol. Further purification of the meconium methanol extracts and 
urine was done with solid phase extraction. Standard curves were created using seven 
calibrators at 0, 5, 15, 30, 50, 75 and 100 ng/mL, and a least square linear regression was 
generated with correlation coefficients > 0.99. 
The lowest limit of quantification (LOQ) was 1 ng/ml for cotinine in urine and meconium. 
The cut-off level of cotinine to distinguish tobacco exposure from no exposure was chosen by 
visually assessing the receiver operating characteristics (ROC) curve. Urine cotinine level 
>15ng/ml was defined as snuff use and urine cotinine <15 ng/ml was categorized as no use. 
In meconium, cotinine level >3 ng/ml was defined as snuff use and cotinine level <3ng/ml 
was categorized as no use. 
Figure 21. ROC for snuff use and maternal urine cotinine (a) and meconium cotinine 
(b) 
 
 
  
a) b) 
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5.4 STATISTICAL METHODS 
The statistical methods used in this thesis are described in detail in each paper. 
Paper I-III 
Associations between tobacco exposure and outcomes were evaluated using multivariable 
adjusted logistic regression models. Results were presented as odds ratios, OR, with 95% 
confidence interval. In order to adjust for the dependence introduced by the fact that mothers 
may contribute with more than one child, the Generalized Estimation Equation method was 
applied. 
Paper IV 
Spearman’s correlation coefficient was used to calculate the correlation between cotinine 
values in maternal urine and in meconium. 
To discriminate snuff users from nonusers, optimal urine cotinine and meconium cotinine 
cut-off levels were determined using receiver operating characteristic curve analyses that 
maximize total probability of correct classification. Sensitivity, specificity, positive predictive 
value (PPV) and negative predictive value (NPV) were calculated and 95% confidence 
intervals were computed by the exact method, using binomial distribution. Moreover, the 
likelihood ratio (LR) for a positive test was calculated as the sensitivity/(1-specificity) and the 
LR for a negative test was calculated as the specificity/(1-sensitivity).
162
 
The agreement between self-reported dose and cotinine levels was analyzed with non-
parametric Wilcoxon signed rank test and Kruskal-Wallis test.  
Linear regression was used to analyze the associations between cotinine levels and birth 
outcomes. 
All data in paper I-IV was analyzed using SAS version 9.2 (SAS Institute, Inc.; Cary, NC). 
5.5 INFORMED CONSENT AND ETHICS 
Papers I-III are population-based register studies and individual consent was not obtained 
from the participants. The participants gave informed consent on paper IV. The studies were 
all approved by the Research Ethics Committee at the Karolinska Institutet, Stockholm, 
Sweden (No 2005/223-31/2, 2006-835-32, 2011/895-32, 2011/1148-32, 02-405, 2009/1725-
32).  
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6 RESULTS  
6.1 MATERNAL CHARACTERISTICS  
Maternal characteristics and tobacco cessation in MBR (papers I-III) 
Our studies demonstrated a high level of correlation between maternal smoking and a low 
socioeconomic status and a low level of education. This was also seen, albeit less 
pronounced, among women using snuff in pregnancy. Moreover, snuff using women were to 
a greater extent teenagers, less educated and multiparous. A higher proportion of snuff using 
women were obese and not living with the father-to-be in comparison to that of nonusers. 
That snuff use is a Swedish habit was evident; as many as 94% of snuff users were born in 
the Nordic countries. Both maternal smoking and snuff use was associated with increased risk 
of cesarean section and preterm birth. Maternal smoking was also associated with increased 
risk of small for gestational age births, whereas the risk for snuff users was in comparison 
with that of nonusers. 
Approximately 60% of snuff users and more than 50% of smokers stopped smoking before 
the antenatal booking. Tobacco cessation was most common among women giving birth to 
their first child. Among mothers who continued to use tobacco, a higher proportion were 
teenage mothers, multiparous and had less than eleven years of education in comparison to 
both nonusers and quitters. Among women who continued to smoke in pregnancy, 58% had 
less than eleven years of education. (Paper 1 and II) 
Table 3. Tobacco use before pregnancy and in early pregnancy in the MBR, 1999-2009 
Tobacco Use Before pregnancy 
  Total No.  
(%) 
Nonuser  
(n) 
Snuff user  
(n) 
Smoker  
(n) 
Missing 
(n) 
E
a
rl
y
 p
re
g
n
a
n
cy
 
Total No. 
(%) 
1,086,213 (100) 773,625 (71.2) 21,994 (2.0) 185,248 (17.2) 102,451 (9.4) 
Nonuser 917,900 (<4.5) 765,145 12,834 97,776 40,669 
Snuff user 11,461 (1.0) 1,237 8,859 732 36 
Smoker 92,092 (8.5) 953 74 85,144 5,626 
Missing 64,014 (5.9) 6,279 211 1,389 56,118 
  47 
 
Table 4.  Maternal and birth characteristics and tobacco use in MFR 
 
paper I, 1999-2006 
 
paper III, 1999-2012 
 
Maternal and birth 
Characteristics 
Nonuser 
 
N=503,460 
Rate % 
 Snuff user 
 
N=7,599 
Rate % 
 Smoker 
1-9 cig./day 
N=41,391 
Rate % 
Smoker 
≥10cig./day 
N=16,928 
Rate % 
 Nonuser 
 
N=1,777,464 
Rate % 
 Snuff user 
 
N=14,671 
Rate % 
 Smoker 
1-9 cig./day 
N=79,783 
Rate % 
 Smoker 
≥10 cig./day 
N=28,459 
Rate % 
                
Age                 
≤ 19 years 1.1  1.9  6.4  3.6  1.4  2.0  6.2  3.8 
Height          -  -  -  - 
≤159 cm 8.6  11.3  11.8  12.4  -  -  -  - 
BMI                
≥30 10.1  12.3  14.8  18.8  11.0  14.0  16.0  20.0 
Multiparity *                
   4.2  7.3  8.0  18.5  18.4  22.6  23.1  39.2 
Education                 
≤9years 5.6  11.3  27.0  34.0  8.0  11.3  26.1  33.0 
Not cohabitant with father-to-be                
 3.4  6.6  14.3  18.5  4.8  7.6  15.8  19.7 
Mother’s country of birth                
Nordic -  -  -  -  80.1  94.0  82.4  85.3 
Cesarean section                
Yes 15.4  18.2  16.5  16.6  -  -  -  - 
Small for gestational age**                
Yes 2.2  2.4  4.7  5.8  -  -  -  - 
*In paper I multiparity is defined as ≥4 children and in paper III multiparity is defined as ≥3 children, why figures are not comparable between papers. 
**Small for gestational age (SGA) was defined as > 2 standard deviations below the mean birth weight for gestational age according to the sex specific Swedish fetal growth curve, Marsal. 
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Maternal characteristics and tobacco cessation in cohort (Paper IV) 
Of the prospectively studied women, only 38 (14%) stopped using snuff during pregnancy, 
and the majority of these stopped between the first and second trimester. All quitters had 
stopped before 28
th
 weeks of gestation. In agreement with the register studies mentioned 
above, women who ceased using tobacco during pregnancy were to greater extent <20 years 
and primiparous. 
Few participants reported exposure to second hand smoke (SHS) in pregnancy. None of the 
nonusers reported daily exposure to SHS, whereas 9% reported exposure to SHS 
occasionally. Two nonusers reported continuous weekly, but not daily, exposure throughout 
pregnancy. Of the snuff users, 17% reported occasional exposure to SHS in early pregnancy 
and 24% in late pregnancy. Twenty-six women were exposed weekly throughout pregnancy 
and 10 were exposed daily. 
Few participants used NRT in pregnancy, and none of the women who stopped using snuff in 
pregnancy were NRT users. Only 4 participants reported use of NRT in early pregnancy and 
7 reported use in the second trimester, two of whom reported use also in the third trimester. 
All participants who reported use of NRT were also reporting simultaneous use of high doses 
of snuff. 
6.2 NEONATAL APNEA 
The most important risk factor for neonatal apnea (Paper I) was preterm birth, and the risk 
increased with decreasing gestational age. For very preterm infants (<32 gestational weeks), 
the adjusted OR was 139 (95% CI: 115-167). There was also a U-shaped association between 
parity and apnea, with increased risk of apnea in infants of primiparous and multiparous (≥4) 
women. 
Snuff use in pregnancy was associated with a twofold increased risk of neonatal apnea, 
adjusted OR 2.2 (95% CI: 1.4-3.2), in comparison to that of nonusers. Maternal smoking was 
associated with lower risk than that associated with snuff use, but the risk increased with 
number of cigarettes smoked, adjusted OR 1.3 (95% CI: 1.0-1.7) and OR 1.5 (95 % CI: 1.1-
2.1), for moderate and heavy smoking, respectively. However, the risk of neonatal apnea was 
no longer significant among infants of smoking mothers when adjusting for gestational age, 
SGA-births and cesarean section but was only slightly attenuated for snuff users. 
Next, sleep apnea (ICD-10 P28.3) was analyzed separately. In infants of snuff users the 
adjusted OR was 2.5(1.4-4.4) and for moderate and heavy smokers adjusted OR was 1.2 
(95% CI: 0.9-1.7) and 1.4 (95% CI: 0.9-2.1), respectively. 
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Table 5. Tobacco use and neonatal apnea UNS, (ICD-10 P28.2-28.4), n=931 
Tobacco 
use  
No. 
 
Rate/ 
1000  
Odds ratio (95% Confidence Interval) 
Crude Adjusted model 1* Adjusted model 2** 
Nonuser 
 
771 
 
1.5 
 
reference 
 
reference 
 
reference 
Snuff user 
 
26 
 
3.4 
 
2.2 (1.5-3.3) 
 
2.2 (1.4-3.2) 
 
2.0 (1.3-3.0) 
Smoker   
          
1-9 cig./day 
 
94 
 
2.3 
 
1.5 (1.2-1.8) 
 
1.3 (1.0-1.7) 
 
1.1 (0.9-1.4) 
≥10 cig./day 
 
40 
 
2.4 
 
1.6 (1.1-2.1) 
 
1.5 (1.1-2.1) 
 
1.1 (0.8-1.5) 
*Adjusted model 1: adjustment for maternal characteristics, such as maternal age, height, parity, education, 
cohabitant with father-to-be **Adjusted model 2: adjustment for maternal characteristics as in model 1 and 
birth characteristics, such as cesarean section, SGA-births and gestational age. 
 
Table 6. Tobacco use and primary sleep apnea, (ICD 10 P28.3), n=416 
Tobacco  use 
 
No. 
  
Rate 
/1000  
Odds ratios (95% Confidence Intervals) 
Crude Adjusted model 1* Adjusted  model 2** 
Nonuser 
 
320 
 
0.6 
 
reference 
 
reference 
 
reference 
Snuff user 
 
14 
 
1.8 
 
2.9 (1.7-5.0) 
 
2.8 (1.7-4.9) 
 
2.5 (1.4-4.4) 
Smoker 
          
1-9 cig./day 
 
56 
 
1.4 
 
2.1 (1.6-2.8) 
 
1.7 (1.2-2.3) 
 
1.2 (0.9-1.7) 
≥10 cig./day 
 
26 
 
1.5 
 
2.4 (1.6-3.6) 
 
2.2 (1.5-3.4) 
 
1.4 (0.9-2.1) 
*Adjusted model 1: adjustment for maternal characteristics, such as maternal age, height, parity, education, 
cohabitant with father to be **Adjusted model 2: adjustment for maternal characteristics as in model 1 and 
birth characteristics as cesarean section, SGA-births and gestational age.  
6.3 ORAL CLEFT MALFORMATION 
The incidence of oral cleft malformations (paper II) was 1.8/1000 births. Maternal age ≥ 35 
years, chronic hypertension, preeclampsia, male sex, multiple births and Nordic country of 
birth were all associated with an increased risk of oral cleft malformations. 
Both maternal snuff use and smoking were associated with an increased risk of oral cleft 
malformations, but varied between subtypes. Whereas risks of cleft lip with or without cleft 
palate were increased following maternal snuff use or smoking, no significant association was 
seen for isolated cleft palate. Infants of mothers who stopped using tobacco (snuff or 
cigarettes) before the antenatal booking were not at an increased risk of oral cleft 
malformations.  
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Figure 22. Maternal tobacco use in early pregnancy and risk of (a) oral cleft 
malformations, (b) cleft lip with or without cleft palate, (c) isolated cleft palate (CP). 
Odds ratios presented with 95% confidence interval  
a) Oral cleft malformations 
 
(b) Cleft lip with or without cleft palate (c) Isolated cleft palate (CP) 
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6.4 EXTREMELY PRETERM BIRTH 
In the study population, 4.94% were born preterm (<37weeks), 4.26% of whom were 
moderately preterm, 0.45% very preterm (<32 weeks) and 0.23% extremely preterm 
(<28weeks). (Paper III) 
Maternal age ≥ 35 years of age, primipara <12 years of education, BMI ≥30 and non-Nordic 
country of birth of the mother were all factors associated with an increased risk of preterm 
birth in the adjusted analysis. 
Maternal smoking in early pregnancy was associated with all categories of preterm birth. The 
risk increased with the number of cigarettes smoked and with decreasing gestational age. An 
increased risk was seen both of spontaneous and medically induced preterm birth and across 
all gestational age strata. Previous smokers who had stopped smoking before the antenatal 
booking were not at an increased risk of preterm birth. 
Maternal snuff use was associated with increased risk of extremely and moderately preterm 
birth, whereas the risk of very preterm birth was of borderline significance. Women using 
snuff three months before pregnancy but who had ceased using it at the antenatal booking 
were not at an increased risk. Snuff use was associated with medically induced extremely 
preterm birth and both spontaneous and medically indicated moderately preterm birth. 
Figure 23. Maternal tobacco use in early pregnancy and risk of preterm birth. Odds 
ratios presented with 95% confidence interval. 
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6.5 ACCURACY OF SELF-REPORTED SNUFF USE  
Self-reported snuff use in pregnancy was found to be valid (paper IV). There was a high 
agreement between self-reported use through questionnaires and maternal urine cotinine 
concentrations in late pregnancy. There was also a high agreement between self-reported 
snuff use in late pregnancy and cotinine in the meconium of the newborn. Furthermore, there 
was a correlation between maternal urine cotinine and cotinine in the meconium of the 
newborn, the correlation coefficient being 0.77 (p<0.001). 
Figure 24. Correlation between the concentration of cotinine in maternal urine and in 
the meconium of the newborn. 
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There were also significant differences between low, moderate and high self-reported doses 
of nicotine and corresponding median cotinine levels in urine and meconium.  
Figure. 25 Snuff use and cotinine levels in maternal urine and meconium  
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Misclassification in the Medical Birth Register 
The information in the Medical Birth Register on snuff use in late pregnancy showed a high 
rate of misclassification. In the cohort, less than 15% stopped using snuff between the 
antenatal booking and week 32. However, according to the MBR register data, as many as 
44% of the (same) cohort population were registered as nonusers in late pregnancy.  
When validating the register data with cotinine levels in maternal urine, the sensitivity was 
only 50% (95% CI: 43-57) and the specificity was 98% (95% CI: 94-100). In late pregnancy, 
45.5% of the MBR registered nonusers (i.e. registered non-users both in early and late 
pregnancy and registered quitters) had cotinine levels above cut-off level in maternal urine.  
As many as 77 % of participants who were registered as having ceased using snuff, i.e. 
registered as quitters, had maternal cotinine values above the cut-off level ≥15ng/ml. 
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Cotinine levels and neonatal growth outcomes 
Of 381 participants in the study cohort, 15 (3.9%) women gave birth prematurely. Among 
snuff users, 11 (4.2%) infants were born preterm, and among nonusers 4 (3.4%) infants were 
born preterm. Among snuff users, two births were extremely preterm and two were very 
preterm, but they were all excluded because of missing information on cotinine as a 
consequence of the preterm birth. With them included, 4.9% were born preterm in the cohort, 
and the proportion of preterm birth among snuff users was 5.6%. 
There was a significantly reduced gestational age of 3.3 days (p<0.01) for infants of mothers 
with cotinine levels in urine above cut- off, as compared to infants of mothers with cotinine 
levels below cut- off (Table 7a).  
Table 7a. Urine cotinine levels and neonatal outcomes in paper IV, n= 307 
Tobacco use 
Crude Adjusted* Adjusted** 
(95%CI) 
mean 
difference 
p 
mean 
difference 
p 
mean 
difference 
p 
Gestational age   
Nonuser  
<3ng/ml 282(280-284) ref  ref  - - 
Snuff user 
≥3ng/ml 278(277-280) -4.13 <0.001 -3.32 <0.01 - - 
Birth weight       
Nonuser  
<3ng/ml 3,653(3,554-3,750) ref  ref  ref  
Snuff user 
≥3ng/ml 3,588(3,513-3,662) -66.1. 0.29 -99.2 0.11 -19.4 0.72 
Length at birth     
Nonuser  
<3ng/ml 50.9(50.5-51.3) ref  ref  Ref  
Snuff user 
≥3ng/ml 50.5(50.2-50.8) -0.39 0.11 -0.44 0.08 -0.02 0.91 
Head 
circumference     
Nonuser  
<3ng/ml 35.3(35.1-35.6) ref  ref  ref  
Snuff user 
≥3ng/ml 35.2(35.0-35.4) -0.06 0.67 -0.10 0.57 -0.11 0.49 
Crude means calculated only for individuals with information on maternal characteristics and urine cotinine. 
Only participants who were categorized as nonusers or snuff users by both urine cotinine levels and self-
reported information through questionnaires were included. Only singleton births were included. 
*Adjusted for maternal characteristics, such as maternal age, bmi, co-habitant with father-to-be and parity. 
**Adjusted for maternal characteristics and gestational age.  
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Infants with cotinine above cut-off level in their meconium also had a significantly reduced 
lower mean adjusted gestational age (-2.6 days, p<0.05) than that of infants with cotinine 
levels below cut-off in their meconium (Table 7b). 
 
Table 7b. Meconium cotinine levels and neonatal outcomes, in paper IV, n= 283 
Tobacco use 
Crude Adjusted* Adjusted** 
(95%CI) 
mean 
difference 
P 
mean 
difference 
p 
mean 
difference 
p 
Gestational age   
Nonuser  
<3ng/ml 281.(280-284) ref  ref  - - 
Snuff user 
≥3ng/ml 278(277-280) -3.61 <0.01 -2.63 <0.05 - - 
Birth weight       
Nonuser  
<3ng/ml 3650(3553-3748) 
ref  ref  ref  
Snuff user 
≥3ng/ml 3585(3502-3667) -65.4 0.32 -98.8 0.12 -32.1 0.56 
Length at birth     
Nonuser  
<3ng/ml 51.0(50.6-51.4) ref  ref  ref  
Snuff user 
≥3ng/ml 50.5(50.2-50.8) -0.46 0.07 -0.47 0.07 -0.19 0.40 
Head 
circumference 
    
Nonuser  
<3ng/ml 35.3(35.1-35.6) ref  ref  ref  
Snuff user 
≥3ng/ml 35.3(35.1-35.5) -0.37 0.85 -0.05 0.77 -0.07 0.67 
Crude means calculated only for individuals with information on maternal characteristics and cotinine in 
meconium. Only participants who were categorized as nonusers or snuff users by both meconium cotinine 
levels and self-reported information through questionnaires were included. Only singleton births were 
included.*Adjusted for maternal characteristics, such as maternal age, bmi, co-habitant with father-to-be and 
parity.**Adjusted for maternal characteristics and gestational age.  
There were no significant differences in mean birth weight, birth length or head 
circumference adjusted for gestational age between newborns of women with maternal urine 
cotinine levels over and below cut-off , nor were there differences between newborn 
meconium cotinine levels over and below cut-off (cotinine level ≥ 3ng/ml) (Table 7 a and b). 
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7 DISCUSSION 
“If younger adults turn away from smoking, the industry will decline, just as a population 
which does not give birth will eventually dwindle.” RJ Reynolds researcher, 1984 
The focus of this thesis is prenatal nicotine exposure in the form of oral moist tobacco, snuff 
and cigarette smoking and effects on the health of the newborn.  
The rationale for the included studies was to study the differences between the effects of 
smoking and snuff on the health of the newborn. The adverse effects of smoking in 
pregnancy have been thoroughly investigated,
1, 45
 and, likewise, animal studies have shown 
that prenatal nicotine is hazardous to the developing fetus.
83, 163
 However, whether maternal 
tobacco use in the form of snuff is safe during pregnancy had not been elucidated. 
Neonatal apnea 
Maternal snuff use was associated with a twofold risk of neonatal apnea. This is the first 
study of snuff use and neonatal apnea, but previous studies on maternal smoking have found 
an association with neonatal apnea.
98
 The risk of sleep apnea was increased almost threefold 
in infants of snuff users in comparison to that of nonusers. 
The risk of apnea associated with maternal smoking was explained by the increased risk of 
preterm birth among smokers. In contrast, in infants of snuff users the risk was not only 
higher than in that of smokers, it also remained significant after adjustment for gestational 
age.  
Neonatal apnea is a sign of disturbances in the cardiorespiratory system and is suggested to 
be associated with an increased risk of SIDS. Preterm birth is a strong risk factor for neonatal 
apnea, and the risk increases with decreasing gestational age.
164
 Prematurity and maternal 
smoking are regarded as the most important risk factors for SIDS,
165
 particularly since the 
back to sleep campaign was introduced.
93
 
SIDS is a rare event, less than 0.2/1000 live born infants yearly in Sweden,
166
 and the 
prevalence of snuff use in pregnancy is 1.1%. The association between snuff use and SIDS 
has not been possible to study because of lack of power. 
SIDS is suggested to be related to a disturbed autonomous control with decreased arousal. In 
addition, a blunted response to hypoxia with a disturbed pattern of breathing, apnea and 
bradycardia is associated with the mechanisms behind SIDS.
94, 95, 165, 167
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Preterm infants and infants prenatally exposed to smoking show similar disturbances in the 
neural control of the cardiorespiratory system, with vascular, cardiac and blood pressure 
hyperactivity.
168
 These similar findings thus represent an effect of immaturity in the 
premature infant and a developmental programming effect in the nicotine-exposed infant. As 
nAChRs are present as early as gestational week 4-5 in fetal development,
137
 nicotine may 
carry out teratogenic effects by binding these receptors, induce apoptosis and affect cell 
programming.
104
 
Nordenstam et al. found decreased heart rate variability among infants of smokers and snuff 
users compared to that of nonusers, also implying disturbances in autonomic control. A 
decreased heart rate variability was found also in infants of snuff users and smokers who had 
ceased using tobacco during pregnancy,
169
 indicating early programming effects of nicotine 
on the development of the nervous system.  
Furthermore, animal studies of prenatal nicotine exposure have shown similar disturbances 
in the cardiorespiratory system as those observed in infants of maternal tobacco use. 
Findings in animal studies of prenatal nicotine exposure include abnormalities in the 
sympathovagal balance, with an increased frequency of apneas and a blunted 
cardiorespiratory response to hypoxia. Changes in breathing patterns, such as a higher 
breathing frequency and a lower tidal volume in the neonatal, have also been observed.
102, 
103, 151, 153
 In addition, prenatal exposure to nicotine leads to a decreased arousal and ability 
to resuscitate, as well as to an impaired catecholamine release from the adrenal medulla, 
followed by a reduced cardiac response to adrenergic stimulation in rat pups.
104
 
As mentioned, the plasma concentration of nicotine remains at a high level for hours after 
snuff use, in contrast to the rapid decline after smoking.
136
 Nicotine also accumulates in the 
amniotic fluid
80
 and the dose of nicotine to which the fetus is exposed may therefore be 
higher in infants of snuff users. This may be an underlying explanation for the higher risk 
of neonatal apneas in infants of snuff users than in infants of smokers. 
Smoking during pregnancy is associated with both increased risk of preterm birth and 
SIDS.
97, 165
 The increased risk of SIDS in smokers may therefore be an effect of both an 
immature nervous system caused by preterm birth and the toxic effect of nicotine on the 
autonomous nervous system.  
Tobacco smoke and nicotine also affect the immune system,
81
 which may influence both 
the susceptibility to infections and the subsequent inflammatory response.
170
 Both preterm 
infants and infants of smokers are more prone to get respiratory infections,
121, 122
 
171
 causing 
a mild hypoxia. Although such infections in most cases are benign, they may induce apnea 
and bradycardia. It is possible that this may cause a serious and even fatal event in the more 
vulnerable nicotine exposed infant. 
170
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Oral cleft malformations 
The association between snuff use in pregnancy and oral cleft malformations has not been 
studied previously. However, the finding that maternal smoking was associated with a 
moderately increased risk of oral cleft malformations is in agreement with previous studies on 
maternal smoking.
106, 172, 173
 The Surgeon General states in their report from 2014 that there is 
sufficient evidence to conclude that a causal relationship between maternal smoking and oral 
cleft malformations exists.
2
  
In the present study, smoking and snuff use in pregnancy were associated with increased risk 
of CL/P, but in contrast to previous studies on smoking in the MBR there was no increased 
risk of isolated CP.
172, 174
 Previous literature is not consistent as to whether smoking increases 
the risk of both CL/P and CP. Most previous studies have found a relationship between 
smoking and CL/P,
120, 175-177
 and others between both CL/P and isolated CP.
114, 178
 In a meta-
analysis Little et al. found a 34% risk increase of CL/P and a 22% increased risk of CP 
associated with maternal smoking.
106
  
The lack of an association between tobacco use and isolated CP in paper II may be due to 
lack of power. Smoking in pregnancy and exposure to second hand smoke has decreased 
considerably in Sweden since the end of the 90’s when the previous studies in the MBR were 
performed.
6
 Furthermore, there is evidence of a dose-dependent association with oral cleft 
malformations.
178
 It is possible that the different results between the present study and 
previous studies in the MBR may be that the dose of nicotine required to cause damage is 
higher for isolated CP than for CL/P.  
The finding that both snuff use and smoking in pregnancy increase risk of oral cleft 
malformations implies that nicotine is involved in the mechanism. The risk was higher for 
snuff users than for smokers, which further strengthens this hypothesis. The dose of nicotine 
to which the fetus is exposed is likely to be higher in infants of snuff users than it is in infants 
of moderate, and possibly also heavy, smokers. Findings in vitro and from animal studies 
have shown disturbances in the fusion of the facial prominences, which further supports the 
theory that nicotine is involved in the mechanism.
115, 116, 179, 180
 
Extremely preterm birth 
Extremely preterm birth is rare, with an incidence of 0.3%-0.4% yearly in Sweden.
6
 
However, morbidity and mortality of preterm birth is increasing with decreasing gestational 
age, and extremely preterm birth is the major cause of neonatal death in most developed 
countries.
74
 Both snuff use and smoking have previously been associated with preterm birth.
62
 
However, the association with extremely preterm birth (<28 gestational weeks) has not been 
studied previously in snuff users.  
Maternal snuff use was associated with increased risk of extremely preterm birth and 
moderately preterm birth, but the risk of very preterm birth was only borderline significant. 
Maternal smoking was associated with increased risk of preterm birth in all gestational ages. 
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The risk increase was higher for smokers than for snuff users. The association with preterm 
birth and smoking was dose-dependent across all gestational ages. 
In addition, smoking in pregnancy was associated with both spontaneous and medically 
indicated preterm birth in all gestational ages. Maternal snuff use was associated with a 
twofold increased risk of medically indicated extremely preterm birth and a moderately 
increased risk of both spontaneous and medically indicated moderate preterm birth. 
The risk of preterm birth was higher for smokers than for snuff users but also dose dependent, 
which implies that both combustion products and nicotine are involved in the mechanism 
underlying preterm birth. It is possible that combustion products and nicotine have synergistic 
effects, leading to a high risk of preterm birth in smokers. 
Several mechanisms through which smoking may contribute to preterm delivery have been 
suggested and include dysfunctional placentation, leading to placental abruption
58, 59, 72
 and 
defect collagen synthesis, leading to premature rupture of the membranes.
3
 Furthermore, 
smoking increases the risk of fetal growth restriction,
1, 45, 83
 possibly via placental 
dysfunction, which is an important indication for medically indicated preterm birth.  
Snuff use has not been shown to be associated with placenta previa or placental abruption. 
60
 
However, there is a lack of studies exploring the associations between snuff use and placenta 
previa and placental abruption. The association between snuff use and risk of fetal growth is 
modest,
63
 implying that although nicotine affects fetal growth, the fetal growth restriction 
caused by smoking is also due to placental dysfunction caused by combustion products.  
Another important indication for medically indicated preterm birth is pre-eclampsia. Maternal 
smoking protects against preeclampsia, supposedly through the vasodilative properties of 
CO.
68, 71
 In contrast, snuff use in pregnancy does not protect against preeclampsia.
70, 71
 
Maternal snuff use is associated with preterm but not term preeclampsia,
70, 71
 suggesting that 
nicotine is involved in the early stages of the disease.
71
 Furthermore, nAChRs are expressed 
in the preeclamptic placenta in nonsmokers, implying that nicotine is involved in the 
development of pre-eclampsia.
181
 However, it was not possible to explore the association 
between preeclampsia and extremely preterm birth in snuff users in paper III, owing to lack 
of power.  
Human labor is supposed to begin with functional progesterone withdrawal leading to 
decidual activation.
77, 182
 At term, decidual activation seems to be mediated by the fetal-
decidual paracrine system. In many cases of early preterm labor, decidual activation rather 
seems related to intrauterine bleeding or an intrauterine infection.
77
 Smoking also affects the 
immune system, increasing inflammation and the susceptibility to infections.
81
 It is thus 
possible that nicotine may influence preterm birth by an effect on the immune system,
81, 137
 
but also through the effect on the endocrine system inhibiting progesterone release.
183
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In conclusion, there is evidence suggesting that both nicotine and combustion products are 
responsible for increased risk of preterm birth, but the underlying mechanisms remain largely 
unexplained. Importantly, mothers who had stopped using tobacco (smoking or snuff use) 
very early in pregnancy, before the antenatal booking, had no increased risk of giving birth 
preterm.  
Validation of self-reported snuff use 
Most epidemiological studies on the effects of maternal smoking are based on self-reported 
information on tobacco use. The information in the MBR on maternal tobacco use is also 
based on self-reported information, with the advantage of prospectively collected data 
minimizing risk of recall bias. However, maternal smoking, and to some extent also snuff use 
in pregnancy, is a social stigma. With increasing knowledge of the hazardous effects of 
tobacco use in pregnancy there is a risk of underreporting use, which in epidemiological 
studies increase risk of misclassification, leading to both under- and overestimation of risks.
48
  
Validation studies using cotinine as the golden standard have shown conflicting results. Most 
of them have concluded that self-reported use is valid,
184-187
 but some have found a 
considerable proportion of underreporting of tobacco use.
47, 188
 George et al. showed that self-
reported maternal smoking is valid in Sweden.
184
  
Most validity studies are based on women participating in a study cohort. Taking part in 
research may influence women to answer more truthfully than they would otherwise. 
Therefore, women willing to participate in research may not be representative of the general 
population smoking in pregnancy. Mattson et al. conducted a study on maternal smoking in 
the MBR, using cotinine in serum samples from the umbilical cord at delivery as well as 
maternal venous samples in early labor, showing that maternal self-reported smoking was 
valid in the MBR.
185
 A methodological problem with the study was that self-reported 
smoking in early pregnancy at the antenatal booking was validated with cotinine in serum at 
delivery. Women who changed their smoking habits in pregnancy or ceased smoking were 
not taken into account. 
Self-reported maternal snuff use has not previously been validated. Moreover, there is no 
information in the MBR on dose of snuff use in pregnancy, whereas smoking is categorized 
as moderate (1-9 cigarettes/day) and heavy (≥10 cigarettes/day) smoking. 
Maternal self-reported snuff use in late pregnancy proved valid in our cohort. Interestingly, 
only14% reported cessation of tobacco use during pregnancy. According to the MBR data on 
the same individuals, 45% stopped using tobacco during pregnancy. Likewise, when 
validating the MBR information in late pregnancy with cotinine in maternal urine, the 
sensitivity was as low as 50%, whereas specificity was high, 98%. Of the registered quitters 
in the MBR in late pregnancy,77% had cotinine levels over the cut-off. 
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Surprisingly, none of the women who ceased using snuff in pregnancy used NRT. In 
addition, the few women actually using NRT were reporting high use of snuff 
simultaneously. This supports previous results of NRT not being effective for tobacco 
cessation in pregnancy.
135
 
A possible explanation for the misclassification in late pregnancy in the MBR is that health 
care personnel fail to ask about snuff use, especially in late pregnancy. England et al. 
concluded that a large proportion of obstetrician/gynecologists never or inconsistently screen 
patients for smokeless tobacco products in the U.S. There was also lack of knowledge of 
potential adverse effects in pregnancy.
189
 Another possible explanation may be difficulties in 
filling in the register form correctly. 
Methodological strengths and limitations 
Papers 1-III are all population-based cohort studies based on data from the Medical Birth 
Register. Self-reported tobacco use is prospectively collected, minimizing the risk of recall 
bias. Maternal socioeconomic characteristics are possible to obtain through linkage to the 
Education Register and the Register of Total Population. 
However, register studies have a number of limitations. There is always a risk of differential 
misclassification of tobacco use with self-reported use not confirmed by biomarkers. 
Smoking in early pregnancy in the Medical Birth Register has been validated and proved 
reliable, but snuff use has not been validated previously. Register studies do not reflect 
patterns of tobacco use or dose of tobacco. Snuff use is merely categorized as yes/no. Use of 
NRT or electronic cigarettes are not registered, there is no information on the tobacco habits 
of the father-to-be and no information on exposure to second hand smoking. 
There is also a problem of unmeasured confounding or residual confounding in register 
studies. Possible confounders, such as maternal substance use, alcohol consumption in 
pregnancy, maternal vitamin substitution and medications, and other life-style factors are not 
possible to obtain from the register. Smoking was associated with low socioeconomic status 
and low level of education. Snuff use was not to the same extent associated with low 
socioeconomic status and low education as was the case with smoking, a finding consistent 
with a study by Kvalvik et al. describing female smokers and snuff users in Norway.
186
 
Paper IV is a cohort study with prospectively collected self-reported data where pattern of 
use and the dose of snuff use may be studied. Information on NRT and second-hand smoking 
was also possible to obtain. In addition, the self-reported tobacco use in late pregnancy was 
validated by cotinine in maternal urine and cotinine in the meconium of the newborn. The 
cohort was linked to the MBR register data, and validation of the MBR data in late pregnancy 
for snuff use was also possible. By comparing the cohort with a regional cohort in the MBR 
the same years, it was possible to conclude that the cohort was representative of the 
population, with the exception of the proportion of snuff users, smokers and nonusers. 
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However, there are limitations in the study design. The women included in the study were 
informed that self-reported snuff use would be confirmed by cotinine, which may influence 
the accuracy of the self-reported use There is also a risk of selection bias, i.e. women willing 
to participate in a validation study on snuff use may differ from the general population on 
basis of exposure. Another limitation is the categorization of snuff use. The high-use cut-off 
was defined as more than 7 pouches a day. This turned out to be too low, as the range of 
pouches used daily in the high-use category was very wide, 7- > 20 pouches a day. Therefore, 
a dose dependency may have been blunted. 
Moreover, some possible confounding factors, such as consumption of alcohol, medication 
and use of vitamins were not obtained through the questionnaires. Information on tobacco 
habits of the father-to-be was not obtained either. 
An important limitation is that the accuracy of self-reported snuff use in early pregnancy was 
not possible to obtain, because maternal urine cotinine was not analyzed in early pregnancy. 
Most register studies on maternal snuff use and smoking are based on self-reported use in 
early pregnancy, why validation in early pregnancy would have been very useful. 
Conclusion and further perspectives 
Nicotine is highly addictive, and smoking cessation in pregnancy has been found very 
difficult to achieve. Neither psychosocial interventions, nor NRT have proved successful.
2, 11, 
132, 135
 Use of nicotine is generally regarded as safer than smoking, and as a consequence snuff 
and new nicotine products, such as electronic cigarettes, are marketed as a safer alternative 
than smoking.
13, 34, 129
 The adverse effects of nicotine on pregnancy and the developing fetus 
are often neglected in discussions of e-cigarettes or snuff as a means of smoke cessation and 
harm reduction.
32, 34, 129
 
Because of population growth, the number of smokers is actually growing in the world 
despite decreasing prevalence in many countries. In some developing countries, smoking 
actually increases.
20
 In developed countries a whole new market of nicotine and non-cigarette 
tobacco products, such as electronic cigarettes, has evolved, attracting young people in 
particular.
190
 Among young people, aged 18 to 24, e-cigarettes are now more popular than 
conventional cigarettes.
191
 E-cigarette use is strongly associated with the use of other tobacco 
products.
191
 The use of new tobacco products and dual use of cigarettes and other nicotine 
sources place high demands on society and the health care professionals regarding preventive 
strategies. England et al. have shown that obstetricians seldom or never screen for nicotine 
products other than tobacco cigarettes and that the knowledge of adverse effects in pregnancy 
is limited.
189
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To conclude, snuff use in pregnancy has adverse effect on pregnancy and the health of the 
newborn. The mechanisms behind the harmful effects of smoking are not clear and for some 
conditions, such as fetal growth and possibly also preterm birth, both nicotine and 
combustion products seem to be involved. The risk increase of fetal growth restriction and 
preterm birth is higher for smokers than for snuff users, and there is evidence of combustion 
products affecting placental function.
2, 3
 In contrast, the risks of adverse effects supposedly 
caused by nicotine, such as neonatal apnea and oral cleft malformation, seem to be higher in 
snuff users than in smokers.  
Of those who cease smoking in pregnancy, the majority stop without counselling or use of 
NRT before the first visit to the prenatal clinic.
55, 133
 However, among those who smoke at the 
antenatal booking, the majority continue to smoke throughout pregnancy. Pharmacological 
and psychological therapies have not proved effective for smoke cessation in pregnancy.
2, 132
 
Strategies for snuff cessation in pregnancy are lacking. In addition, because of lack of 
adherence to NRT, safety has been difficult to study.
135
 
With growing knowledge about the detrimental effects of snuff, containing merely nicotine, 
caution is recommended regarding use of NRT and e-cigarettes in pregnancy. No safe level 
of prenatal nicotine exposure has been established.
192
 Nicotine, in any form, is not to be 
considered safe and should be avoided in pregnancy. 
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Figure 26. Advertising for electronic cigarettes 
 
Source: From the collection of Stanford Research Into the Impact of Tobacco Advertising 
(tobacco.stanford.edu). 
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